2021
年度報告
2
4
8
53
152
153
188
196
243
271
277
382
387
1 2021
Ranjeev Krishana
Donald W. Glazer
Anthony C. Hooper Michael Goller
Anthony C. Hooper 2
Alessandro Riva 1
Margaret Han Dugan 1
Donald W. Glazer
Corazon (Corsee) D. Sanders 2
Michael Goller
Margaret Han Dugan 1
Ranjeev Krishana
Michael Goller
Thomas Malley
Thomas Malley
Alessandro Riva 1
Alessandro Riva 1
Corazon (Corsee) D. Sanders
3
Anthony C. Hooper
Thomas Malley
Anthony C. Hooper
Margaret Han Dugan 4
Corazon (Corsee) D. Sanders
Ranjeev Krishana
Corazon (Corsee) D. Sanders 2
* 2022 1 31
1. 2022 2 1
2. 2021 2 24
2021 2
(FCG, FCS)
Vistra Corporate Services (HK) Limited
Scott A. Samuels
5
Mourant Ozannes
183
17 1712-1716
Mourant Governance Services (Cayman) Limited
94 Solaris Avenue, Camana Bay
Mourant Governance Services Grand Cayman KY1-1108
(Cayman) Limited Cayman Islands
94 Solaris Avenue
Camana Bay
Grand Cayman KY1-1108
Cayman Islands 06160
www.beigene.com
3. 2021 2 24
4. 2022 2 25
5. 2021 6 30
3 2021
2021 4
5 2021
2021 6
7 2021
3
(BTK)
PD-1
PARP1 PARP2
(EU)
13
2,200
30 90
30
3 14,500
CMO
2010 23
8,000
2021 8
1. 700
ociperlimab TIGIT
BGB-11417 BCL2 2022
2022 2023 OX40 TIM3 PI3Kδ HPK-1
50
2.
2,200
CRO
9 2021
3.
3,100
4.
(WM)
45
5.
2021 10
2022 2 28
R/R MCL1 WM BTK
R/R MZL 1
R/R MCL2
R/R CLL/SLL2 R/R WM2
3
WM
1L NSCLC PD-1
2/3 L NSCLC R/R BLA4
2
2/3L HCC 2
R/R PD-L1+UC 2
3L BRCA 2
PARP
2
RANK
(SRE) 2
R/R 2
CD19 CD3
T (BiTE)
R/R 2
R/R
11 2021
DNA
Castleman IL-6
2
GD2
VEGF
5
BRAF 7
5
MEK 7
VEGFR 7
6
mTOR 7
ALK NSCLC ALK 7
2021 12
1. 2.
3. 27 (EU)
4.
(ESCC) 5. (NSCLC)
6. (VEGF) 7. 2021 12
19
ALK= BLA= BRAF=B CLL=
HCC= MCL= MEK= mTOR=
MZL= NSCLC= R/R= SLL=
UC= VEGFR= WM =
zanubrutinib (BTK)
BTK BTK B (BCR)
BTK BCR BTK
B BTK
13 2021
2019 11 (MCL)
(WM) CD20
(R/R) (MZL) MCL MZL
FDA
(CLL) (SLL) ( sNDA )
(PDUFA) FDA 2022 10 22
WM 27
( EMA )
MZL CLL
MCL
CLL SLL R/R WM ( NMPA )
CLL SLL sNDA 2021 12
WM
( NSHA ) ( NRDL )
WM MCL WM MCL R/R MZL
R/R MCL R/R WM 2022 2 28 45
2021 14
(NHL) (HL)
B T B 85% NHL
B 2021 BTK 80
55 2026 BTK 150
tislelizumab 1(PD-1)
IgG4 Fc γ(FcγR)
T
2022 2
(NSCLC)
NSCLC
NSCLC
(NMPA)
(cHL)
12 PD-L1 (UC)
(HCC)
2020
cHL UC NRDL 2021 NSCLC
NSCLC HCC 5
15 2021
NMPA ( CDE ) 3
( BLAs )
(MSI-H) (dMMR)
(ESCC)
(NPC)
17 13 3 4 2
2021 1
FDA
ESCC BLA FDA PDUFA 2022 7 12
PD-1/PD-L1 2021 305 2022
PD1/L1 24
2025 500
2021 16
pamiparib 1(PARP1) PARP2
PARP-DNA
1,300
2021 5
BRCA(gBRCA)
2021
NRDL
PARP (OC) (GC) PARP
XGEVA denosumab RANK (RANKL)
(MM) (SRE)
(GCTB)
70
2019 5
GCTB 2020 11 SRE 2020 7
2020 12
GCTB
17 2021
GCTB
2019 2,086 GCTB
GCTB
GCTB
SRE
SRE
SRE
MM SRE
BLINCYTO CD-19 CD3 T
T (BiTE) 60
(ALL)
2020 12 ALL
2021 8
ALL
100,000 0.69 ALL 15%
B ALL
CAR-T tisagenlecleucel FDA 25
B ALL FDA clofarabine
2021 18
60
(MM)
2021 7 R/R MM 2022 1
2006
2018
Ixazomib
2013
(MM) 2018 2
NMPA
MM
2019 20,700 MM
MM MM
2006
ixazomib 2019 CD38 DARZALEX
daratumumab
(CSCO) R/R MM
2017 6
2019 11
2020 11 NMPA
19 2021
DNA
2017 4 2 (MDS)
(CMML) (AML) 20-30% 2018 1
MDS
2019 22,100 MDS 70 MDS 2
MDS 0.4 1.1 30% AML
2 MDS (CCR)
2009
50% MDS
MDS
2018 10
ABRAXANE
2020 3 ABRAXANE
2020 3 25 NMPA
ABRAXANE
2021 10 180 ABRAXANE
ABRAXANE ABRAXANE
ABRAXANE
2021 20
EUSA Pharma
SYLVANT 6(IL-6)
(HIV) 8(HHV-8) Castleman (iMCD)
2021 12 (HIV) 8(HHV-8)
Castleman (MCD) MCD(iMCD)
6,500 7,700 Castleman (CD) 75% Castleman 25% HHV-8
MCD HHV-8 iMCD MCD CD
HHV-8 MCD
β dinutuximab beta GD2
NMPA
12
(R/R)
100 19 5
9
β 2021 12
21 2021
(BAT1706)
NSCLC
NMPA 2021 11 2021
(NSCLC)
2020 11
EMA FDA BLA
2021
43
2021 22
14 95%
(BMI)
2017
10-15% 2019 7
2022
2021 12
2022 1 1
5 2021 3 2
(EGFR)
(ALK) 2021 6
2021 NRDL
23 2021
(HCC) 2021 6
2021 NRDL
2021 1 2021 NRDL
PD-L1 12
UC 2020 4 2020 NRDL
2 (cHL) 2019 12
2020 NRDL
3 2021 11 1 2
(WM) 2021 6
2021 NRDL
(MCL) 2020 6
2020 NRDL
(CLL)
(SLL) 2020 6 2020 NRDL
NRDL
BRCA(gBRCA)
2021 5 2021 NRDL
2021 24
2017
2019
2018 2020
2018 (VBP) GPO
4+7 4 7 11 2018
2019
(QCE) (BE)
(Medicare) (Medicaid)
(PBM)
myBeiGene
(Co-Pay)
25 2021
2022 2 28
1a 1b 2 * 2 ** 3
WM1
BTK
PD-1
PARP
2021 26
1a 1b 2 * 2 ** 3
1L NSCLC
1L SCLC
(TIGIT)
1L NSCLC
1L HCC
+ mirdametinib
BGB-A425
(TIM-3)
BGB-A333
(PD-L1)
BGB-A445 (OX40)
BGB-11417
(Bcl-2)
BGB-10188
(PI3K Delta)
BGB-15025
(HPK1)
BGB-23339
(TYK2)
* 2 3 2 **
R/R ∧
R/M
1
2021 3 1 2021 10 7 27 2021
11 23 2021 12 14 2022 2 17 2022 2 24
27 2021
2022 2 28
1b 2 * 2 ** 3
sotorasib
tarlatamab
pavurutamab
AMG 176
AMG 330
AMG 427
acapatamab
AMG 509
AMG 199
AMG 650
AMG 650
AMG 994
AMG 256
Sitravatinib
zanidatamab
ZW49
BGB-32451
SEA-CD70
DKN-01
LBL-007
vebicorvir
(ABI-H0731)
ABI-H3733
* 2 3 2 **
∧ ∧∧ Mirati
BiTE HLE BiTE
sitravatinib Sq NSCLC 3 SAPPHIRE ZW25 Assembly
vebicorvir 2 ABI-H3733 1
AML HLE BiTE T GC/GEJ
HCC IND MEL MM NHL
N/SCLC OC RCC SM (1) MapKure
SpringWorks Therapeutics
2021 28
SEC
SSE
BTK
BTK
BTK
1
24 BTK
2022 2
5 43
Adium Pharma NewBridge Pharmaceuticals Erkim
Nanolek Medison
4 3 5
2
29 2021
WM 3 ASPEN NCT03053440
CLL/SLL
3 SEQUOIA NCT03336333 CLL/SLL
3 ALPINE NCT03734016 SEQUOIA ALPINE
3 MCL 3 (NCT04002297)
2 MCL
WM CLL/SLL NCT03206970
NCT03332173 NCT03206918 MAGNOLIA NCT03846427
2 ROSEWOOD NCT03332017
DLBCL CLL/SLL
CLL/SLL
2022 2 FDA CLL/SLL
(sNDA) (PDUFA) FDA
2022 10 22 (EMA) MZL CLL
10 2022
CLL/SLL ALPINE 2022
2 ROSEWOOD
PD-1
PD-1
17 13 3 4 2
2021 30
NSCLC 3
(NCT03358875)
NSCLC 3
NCT03594747 NCT03663205
SCLC 3 (NCT04005716)
NSCLC 3 (NCT04379635)
HCC 3 (NCT03412773)
HCC 2 (NCT03419897)
3
(NCT03777657)
3 cHL
NCT04486391
cHL 2 (NCT03209973)
31 2021
3 (NCT03967977)
2 (NCT04004221)
ESCC
ESCC 3 (NCT03430843)
ESCC 3 (NCT03783442)
ESCC 3
(NCT03957590)
MSI-H/dMMR 2 (NCT03736889)
3
(NCT03924986)
2022 1 35 9,000 3,000
11
2021 32
PARP1 PARP2
pamiparib 1(PARP1) PARP2
DNA PARP
2021 5
BRCA(gBRCA)
3
(NCT03519230) BRCA HER2 2 (NCT03575065)
2 ( N C T03427814) 1 b /2
(NCT03150862)
2022 3
(BGB-A1217) TIGIT
( B G B - A1217) TIGIT I g G1
3 NSCLC
AdvanTIG-301(NCT04866017) AdvanTIG-302(NCT04746924)
800 6
33 2021
2021 12
Ociperlimab
AdvanTIG-202 (NCT04693234)
2022 2
Lifirafenib(BGB-283) BGB-3245 RAF
Lifirafenib RAF Lifirafenib
BRAF V600E V600E BRAF KRAS/NRAS
lifirafenib (MAPK) BRAF BRAF
KRAS/NRAS lifirafenib
NSCLC
SpringWorks Therapeutics, Inc. (SpringWorks) 1b
(NCT03905148) lifirafenib SpringWorks MEK mirdametinib (PD-0325901)
SpringWorks MapKure, LLC
RAF BGB-3245 MapKure BGB-3245 v-RAF
B (B-RAF) 1 (NCT04249843)
2021 34
Sitravatinib
2018 1 Mirati Therapeutics,Inc(Mirati) Mirati sitravatinib
Sitravatinib
RET TAM TYRO3 Axl MER
VEGFR2 KIT Mirati sitravatinib
2019 sitravatinib NSCLC 3 SAPPHIRE
(AACR)2021 sitravatinib
PD-1/L1 (PROC) 1b
(NCT03666143) sitravatinib
sitravatinib
BGB-11417 Bcl-2
BGB-11417 Bcl-2 BGB-11417
(IND) Bcl-2
Bcl-xL
1 (NCT04277637)
BGB-11417 B
2022 BGB-11417
BGB-A445 OX40
BGB-A445 OX40 BGB-A445 OX40
OX40 BGB-A445
BGB-A445 TLR9
PI3Kδ sitravatinib BGB-A445
1 (NCT04215978) 2022 BGB-A445 (OX-40)
35 2021
ZW25(zanidatamab) HER2
Zanidatamab HER2 Azymetric Zymeworks Inc.
zanidatamab
zanidatamab HER2 1/2
(NCT04215978) zanidatamab zanidatamab
PD-1 zanidatamab
HER2 2b (NCT04466891) 2021 3
(NCT05152147) zanidatamab HER2
2022 2L
BGB-A425 TIM-3
BGB-A425 T 3(TIM-3) IgG1
BGB-A425 1/2 (NCT03744468)
BGB-15025 HPK1
BGB-15025 HPK1 HPK1 TCR
HPK1 T BGB-15025
2021 BGB-15025
1 (NCT04649385) 2022
BGB-15025
2021 36
10
50
12
CMO
CMO
(GMP) GMP
37 2021
13,000 1
2 x 500
6 50,000
100,000
2019 9 2020 12 24,000 2021 12
40,000
64,000
42 17
2022 I95
100
2021 38
CMO CRO
Catalent Pharma Solutions,
LLC ( Catalent ) Catalent
(API)
Boehringer Ingelheim
Biopharmaceuticals (China) Ltd. ( Boehringer Ingelheim ) Boehringer
Ingelheim
CMO
30
39 2021
CRO API
30 60
2019 10 31 BeiGene Switzerland GmbH
2020 1 2
2021 40
12.5
Sotorasib(AMG 510)
Sotorasib(AMG
510)
41 2021
2019 10 31
2020 1 2 15,895,001
206,635,013 20.5% 27.8
13.45 174.85
(i) (a) (b) (c)
(ii) (a) (b)
5% (iii) (a) (b)
(i)
(ii) 12
5%
10%
(b)
20.6%
2021 42
2020 3 17
2020 9 24
20.6%
20.4% (i)
(ii)
2020 12 1
(a) 20% (b)
60 (c)2023 12 1
2021 1 11
2021 2 26
6.5
13 2.5
43 2021
(i)
(ii) PD-1 (spartalizumab) BLA
spartalizumab
120
180
2021 44
Ociperlimab
2021 12 19
TIGIT ociperlimab
3 2023
2023 6 7
7.45 11.5
ociperlimab
ociperlimab
ociperlimab
ociperlimab
ociperlimab
ociperlimab
ociperlimab
ociperlimab
ociperlimab 50%
25%
ociperlimab
ociperlimab ociperlimab
45 2021
ociperlimab
120 ociperlimab
180
(i)
(ii) (Hart-Scott-Rodino
Antitrust Improvements Act)
2017 7 5
2017 8 31
ABRAXANE
2020 3 25 NMPA ABRAXANE
2021 10 180
ABRAXANE ABRAXANE
ABRAXANE
2021 46
10
2022 1 22 40 24
PCT
PCT
FDA
FDA
2021 6 1
47 2021
2022 1 31
1
2034
2034
B 2034
2037
2034
2033
2033
2033
2033
2033
2033
2033
2033
2033
2031
2031
2031
2031
2036
2038
2031
2031
2036
2038
(1)
2021 48
2022 1 31
2023
2023
2023
2023
2022 1 31
2022
2025
NMPA
49 2021
20
FDA
FDA 14 2021 6 1
BeiGene
BeiGene
2021 50
CD20 B
BTK
BTK
2013 FDA
MCL 90
BTK CALQUENCE (acalabrutinib)
2017 FDA
MCL 2019 11 CLL/SLL
2017
2020
–FDA PD-1 PD-L1
BMS
BAVENCIO
LIBTAYO
JEMPERLI
PD-1 PD-L1
2022 2 1 PD-1
PD-L1
40 PD-1 PD-L1
51 2021
PARP 2018 8
2019 12 NMPA
2020 12
TIGIT Agenus Arcus
Compugen iTeos Therapeutics Mereo Biopharma Seagen
TIGIT 3
2021 52
53 2021
2017
ABRAXANE
2019 10
KYPROLIS
2020 1 2
2019 5 2020 12 2021 7
2021 54
2019 11 BTK
(MCL)
MCL (CLL)
(SLL) 2020 6 WM 2021 11
2019 12 (cHL)
2021 5
55 2021
FDA
FDA
FDA FDA
(NMPA) (EMA)
FDA
2021 56
FDA NMPA
EMA
57 2021
2021 58
59 2021
FDA NMPA EMA
FDA NMPA EMA
2020 3 25
NMPA ABRAXANE
2021 10 180
ABRAXANE ABRAXANE ABRAXANE
Medicare
Medicaid
2021 60
(Centers for Medicare and Medicaid Services, CMS)
CMS
FDA
61 2021
2021 62
(federal Anti-Kickback Statute)
(federal False Claims Act)
2003 4
(April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical
Manufacturers)
63 2021
Medicare Medicaid
( GDPR )
2021 64
65 2021
2021 66
67 2021
(IRB)
CRO
GMP
IRB
2021 68
69 2021
NMPA
2020 3 25 NMPA
ABRAXANE
2021 10
180 ABRAXANE
ABRAXANE
ABRAXANE
2021 70
FDA NMPA EMA
FDA NMPA EMA
71 2021
FDA
2021 5 FDA
2020 7 FDA
FDA
FDA
FDA 2021 5
2021 4 FDA
2021 5
FDA FDA
2021 7 FDA
FDA 2020 2021 FDA
FDA
2021 72
FDA
FDA
FDA IND (i) GCP
(ii)FDA
FDA (i)
(ii) (iii) FDA
FDA FDA
FDA
FDA
FDA
73 2021
FDA NMPA EMA
2020 3 25 NMPA
ABRAXANE
2021 10
180 ABRAXANE
ABRAXANE
ABRAXANE
FDA NMPA EMA
FDA
NMPA EMA
FDA NMPA EMA
FDA NMPA EMA
2021 74
FDA NMPA EMA
FDA NMPA EMA
FDA NMPA
EMA
75 2021
2021 76
2020 1 ABRAXANE
ABRAXANE
2020 3 25 NMPA ABRAXANE
ABRAXANE
2020 8
77 2021
2021 6
Hatch-Waxman
FDA
FDA
30
2021 6 1
2020
NMPA (NIPA) 2021
7 4
2021 78
FDA NMPA EMA
FDA NMPA EMA
FDA NMPA EMA
FDA NMPA EMA
FDA NMPA EMA
FDA NMPA
EMA
FDA NMPA EMA
(AE)
(SAE)
SEC
AE SAE
(IRAE)
79 2021
(REMS)
2021 80
Affordable Care Act
2017 2021
2021 12 31 50
81 2021
12.5
2017
2019 2020
2021
2021 82
2021 2020 2019 12 31 13 13
7.503 2021 2020 2019
14 16 9.506 2017
83 2021
2017 9 2019
12
2021 84
85 2021
2021
12 31 44 720 22
2021 12 31
2021 86
18
87 2021
(USPTO)
2021 88
89 2021
2021 90
91 2021
2023
2024
2027
PARP 2027 2031 TIGIT PD-1
ociperlimab 2034
2021 92
FDA
2021 6 1
93 2021
2021 94
Catalent Pharma Solutions, LLC Catalent
95 2021
2018 2019 2020 ABRAXANE
NMPA ABRAXANE
FDA
2020
NMPA ABRAXANE
2021 96
2020 3 25 NMPA ABRAXANE
2021 10 180
ABRAXANE
ABRAXANE
ABRAXANE
97 2021
GMP
2020 3 25 NMPA
ABRAXANE
2021 10
180 ABRAXANE
ABRAXANE
ABRAXANE
2021 98
ABRAXANE
NMPA
2017 8
ABRAXANE 2020 3 25 NMPA
ABRAXANE
2021 10 180 ABRAXANE
ABRAXANE ABRAXANE
2019
2021 1
PD-1
2021 12
TIGIT ociperlimab
99 2021
2017
2019 6 2021 10 ABRAXANE
(i)
(ii) (iii)
2021 100
101 2021
HGRAC
KRAS G12C LUMAKRAS (sotorasib)
HGRAC
2021 102
103 2021
2021 5,100 57% 8,000
2021 104
105 2021
2019
2021 106
2021 3 1
2021 4 15
107 2021
FDA NMPA EMA
FDA NMPA EMA
FDA NMPA EMA
2021 108
1934
2002
404
109 2021
206,635,013
20.5%
2021 110
(i) (ii)
(iii)
2020 2
111 2021
2021 112
113 2021
2021 114
115 2021
2018
General Data Protection Regulation (EU)2016/679
2020 1 31 2020 12 31
2021 1 1 2018 2020
12 31 GDPR
2021 116
2017
2021 9 1
2021 11 1 (i)
(ii)
2021 11 14
1 31
117 2021
2021 10 29
2021 118
119 2021
2019 12 2020 1
2021 120
2019
121 2021
2021 122
2017
LIBOR 2021 LIBOR
LIBOR 2020 11 30
2021 12 31 LIBOR 2023 6 30 LIBOR
LIBOR LIBOR
LIBOR LIBOR
123 2021
OECD/G20
(BEPS)
2020 2019
1 1 2.0 2019 4 30
2019 1 1 2019 7 1
2019 1 1
2021 124
125 2021
2021 7
VIE 2021
12 24
VIE
ADS ADS
10-K
2014
2021
2021 126
2021 12 16
2024
2020 12 18
2021
2024 2022 3 30
2022 2 28
10-K
2022 3 8
Ernst & Young LLP
2022 12 31
127 2021
2021 10
Ernst and Young LLP 2022 12 31 2022
10-K 2022 10-K
Ernst and
Young LLP
2021 128
2023
2021 6 22 2002
(15 U.S.C. 7214(i)) 104(i)
2022 2 4 2022
2021
2024 2023
Ernst and Young LLP 2022 10-K
2022 10-K
129 2021
2012
2014
2015
2021 130
1979
2020 1
2021 1 18
131 2021
2020 3
2021 7 6
2021 132
10% 50%
2021 12 31 7.996
2016
133 2021
10%
5%
2018
(i) (ii)
(iii) (iv)
2021 134
25%
10%
20%
10% 20%
25%
10%
135 2021
2021 136
137 2021
2021 138
139 2021
ADS BGNE 06160
ADS
2022 2 14 1,334,804,281 0.0001 973,604,879
74,892,683 13 115,055,260
2021 140
2020 5 11 S-3 300,197,772
17,297,026 224,861,338
141 2021
2021 142
143 2021
21
14
2021 144
145 2021
2021 12 15
1933
2021 146
147 2021
2018
0.2% 0.1%
2021 148
2022 2 14 55%
149 2021
(1) 75% (2) 50%
(PFIC) 2021 12 31
(Internal Revenue Service)
2021 150
F
50%
50%
10%
10% 1986 (Internal Revenue Code
of 1986)
151 2021
12 31
2017 2018 2019 2020 2021
24,428 130,885 222,596 308,874 633,987
213,959 67,335 205,616 – 542,296
238,387 198,220 428,212 308,874 1,176,283
233,413 169,515 357,022 238,217 1,011,377
91,064 689,829 943,586 1,618,194 1,438,588
93,299 674,033 950,578 1,600,523 1,413,354
93,105 673,769 948,628 1,596,906 1,413,354
(%) 98% 86% 83% 77% 86%
(%) -39% -340% -222% -518% -120%
12 31
2017 2018 2019 2020 2021
239,602 740,713 620,775 1,390,005 4,382,887
597,914 1,068,509 364,728 3,268,725 2,241,962
763,509 1,697,390 862,384 3,885,491 6,014,325
1,046,479 2,249,684 1,612,289 5,600,757 8,645,949
362,248 496,037 633,934 1,731,514 2,402,962
14,422 14,445 16,150 – –
684,231 1,753,647 978,355 3,869,243 6,242,987
(1) 10-K
2021 152
3
(BTK)
PD-1
PARP1 PARP2
13
2,200
30 90
30
3 14,500
2010 23
8,000
153 2021
2022 4 19 (ASCO) 3
RATIONALE-309
(RM-NPC)
2022 4 15 NMPA
(ESCC)
2022 4 11 3 ALPINE BTK BRUKINSA (R/R)
(CLL) (SLL)
2022 4 6 (MAA)
EMA ESCC (NSCLC)
NSCLC
NSCLC
NSCLC EGFR ALK
2022 3 11 NMPA PD-1
(MSI-H) (dMMR)
2022 2 22 FDA
CLL SLL sNDA CLL
(PDUFA) FDA 2022 10 22
2022 2 22 EMA BTK
(CLL)
(MZL)
2022 2 17
(WM) WM
2022 1 28 NMPA
(CLL)
(SLL) sNDA
(BTD)
2021 154
2022 1 20 NMPA
sNDA WM
2022 1 6 NMPA PD-1
NSCLC
2021 12 20
TIGIT (ociperlimab) ociperlimab
2023
ociperlimab
ociperlimab
ociperlimab
5
2021 12 20 (BIC)
BIC
2021 12 15
WM WM
2021 12 13
LBL-007 LBL-007 LAG-3
2021 12 2 PD-1
PARP
2022 1 1
2021 12 2 NMPA EUSA
(HIV) 8 (HHV-8) Castleman (MCD)
MCD(iMCD)
155 2021
2021 11 23
115,055,260 0.0001 2021 10 31
8.62%
2021 11 30
192.60 1.00
0.81996 1.00 6.3924 234.89
(ADS)391.68 2021 12 14 2021 12 15
688235
222 35
2021 11 23
WM
WM 27
2021 11 23
42
2021 11 14 NewBridge Pharmaceuticals
(MCL)
2021 156
1. 700
ociperlimab TIGIT
BGB-11417 BCL2
2022 2022 2023
OX40 TIM3 PI3K delta HPK-1 50
2.
2,200
CRO
157 2021
3.
3,100
4.
WM
45
5.
2021 158
2021 1
(1)
(2)
159 2021
2021 12
TIGIT
5
(1) (2)
(3)
2021 160
161 2021
BTK
PD-1
TIGIT
PARP1 PARP2
BGB-15025 1(HPK1)
BGB-11417 Bcl-2
BGB-A445 OX40
BGB-16673 BTK CDAC
BGB-A425 TIM-3
sitravatinib Mirati Therapeutics, Inc. Mirati
ZW25(zanidatamab) ZW49 Zymeworks Inc. Zymeworks HER2
(BAT1706)
2021 162
163 2021
ADS
2021 164
2021 12
165 2021
2021 2020 12 31
2021 2020 12 31
12 31
2021 2020 %
633,987 308,874 325,113 105.3%
542,296 – 542,296
1,176,283 308,874 867,409 280.8%
164,906 70,657 94,249 133.4%
1,459,239 1,294,877 164,362 12.7%
990,123 600,176 389,947 65.0%
750 846 (96) (11.3)%
2,615,018 1,966,556 648,462 33.0%
(1,438,735) (1,657,682) 218,947 (13.2)%
(15,757) 1,998 (17,755) (888.6)%
15,904 37,490 (21,586) (57.6)%
(1,438,588) (1,618,194) 179,606 (11.1)%
(25,234) (17,671) (7,563) 42.8%
(1,413,354) (1,600,523) 187,169 (11.7)%
– (3,617) 3,617 (100.0)%
(1,413,354) (1,596,906) 183,552 (11.5)%
2021 166
2020 12 31 3.089 2021 12 31
8.674 12
2021 2020 12 31
12 31
2021 2020 %
633,987 308,874 325,113 105.3%
484,646 – 484,646
53,671 – 53,671
3,979 – 3,979
542,296 – 542,296
1,176,283 308,874 867,409 280.8%
12 31
2021 2020 %
255,119 163,358 91,761 56.2%
217,987 41,702 176,285 422.7%
70,065 47,372 22,693 47.9%
19,591 29,975 (10,384) (34.6)%
ABRAXANE – 17,770 (17,770) (100.0)%
45,956 8,496 37,460 440.9%
12,515 – 12,515
12,754 201 12,553 6,245.3%
633,987 308,874 325,113 105.3%
167 2021
2021 12 31 6.34 3.089
2020 7 2021 8
2021 3 1
2022 1 1
2021 12 31
5,750 2021 12 31
2021 12 31
2.18 422.7% 2021 12
31
1.157 1,820 MCL
FDA WM MZL 2021 12 31
1.012 331% CLL SLL
2021 12 31
2.551 56.2% 2021
12 31
2021 3 2022 1
2021 4,560
2021 12 31 5.423
4.846
2021 12 31 5,370
400 3 2020 12 31
2020 12 31 7,070 2021 12 31 1.649
2021 168
2021 12 31 4.691 2020 12 31
2.382 77.1%
2021 12 31 74.0% 2021
2021 12 31
2020 12 31
2020 12 31 12.949 1.644 12.7%) 2021
12 31 15 2021 2020 12 31
12 31
2021 2020 %
477,761 502,399 (24,638) (4.9)%
83,500 109,500 (26,000) (23.7)%
1
115,464 117,005 (1,541) (1.3)%
676,725 728,904 (52,179) (7.2)%
782,514 565,973 216,541 38.3%
1,459,239 1,294,877 164,362 12.7%
1. 2021 12 31 2.28 1.155
1.125
2021 12 31
CRO
169 2021
2.165
1.09
5,240
2,140
1,770
1,610
2020 12 31 6.002 3.899 65.0%
2021 12 31 9.901
1.757
1.191
5,930
3,590
2021 170
2020 12 31 200 1,780
888.6% 2021 12 31 1,580
2020 12 31 3,750 2,160 2021 12 31
1,590 2021 12 31 Leap Therapeutics
2020 12 31
MapKure LLC
2021 12 31 2,520 2020 12 31
1,770 2021 12 31
2021 12 31 (1) 28
(2) 244 38 (3)
23.3
2020 12 31 60.4 699.8% 2021 12 31 483.1
2021 12 31 Ociperlimab 300
171 2021
2020 12 31 89.3 171.7% 2021 12 31 242.6
2021 2020 12 31
12 31
2021 2020
87,239 71,341
58,579 30,392
12,010 12,651
5,052 6,619
1,695 1,347
78,538 25,996
27,060 11,666
270,173 160,012
2020 12 31 160.0 68.8% 2021 12 31
270.2 (i) (ii)
2020 12 31 357.7 64.3% 2021 12 31
587.6 2021 11 42
2021 172
2021 2020 12 31 262.4 232.0
12 31
2021 2020
3 257,977 230,638
3 6 3,210 312
6 1 1,110 147
1 103 860
262,400 231,957
2021 2020 12 31
12 31
2021 2020
139,966 106,765
213,922 143,302
71,560 66,131
45,661 14,373
59,639 11,874
27,307 3,699
558,055 346,144
2020 12 31 346.1 61.2% 2021 12 31
558.1 (i)
(ii) (iii) 2021
173 2021
2021 12 31
12 31
2021 2020
4,382,887 1,390,005
2,241,962 3,268,725
629,678 518,652
2021 2020 12 31
14 16 2021 12 31 50
2017 9
2021 12 31
12
2021 6 28 2021 1
2021 12 15
192.60
391.68 115,055,260
34
2021 1
6.5 2021 12
TIGIT
2022 1 3
2021 12 31
2021 174
2021 2020 12 31
12 31
2021 2020
1,390,005 620,775
(1,298,723) (1,283,461)
640,659 (3,168,366)
3,636,911 5,202,826
14,035 18,231
2,992,882 769,230
4,382,887 1,390,005
2021 12 31 13 14
1.183 2.33
2020 12 31 13 16
1.665 1.506
175 2021
2021 12 31 6.407 21
2.629 4,340 4,350 850
31
2020 12 31 32 57
1.175 1.095 28
2021 12 31 36 2021 12
34 4.064
9,280 5,000
1,680 3.218
2020 12 31 52 28
21
9,310 4.339
1.443 5% 2,870
2021 176
2021 12 15 217
SEC
2020 5 SEC
177 2021
2021 12 31
70,218 24,225 45,993
168,687 110,345 58,342
629,678 427,565 202,113
57,299 24,336 32,963
791,059 244,800 546,259
12,750 4,250 8,500
27,985 5,659 22,326
7,814 1,604 6,210
42,394 42,394 –
1,807,884 885,178 922,706
2021 12 31 1.687
7,600 BMS 9,270 BMS
2021 178
4.276 2.021
15
12.5
2021 12 31
8
1,500 2021 12 31
1,280
2021 12 31
2,800
2021 12 31
160
179 2021
2021 12 31 4,240
42
7,520
2021 12 31
57
2
2021 180
NRDL
181 2021
2021 182
2
2021 12 31 2020 12 31 44 14
720 810 22 33
2021 12 31
183 2021
100 2021 12 31
1,510 670
2021 12 31 2020 12 31 483,113,000 60,403,000
1994
2021 184
2005
2021 2020 12 31 2.3% 6.3%
2021 12 31
2021 12 31 2020
12 31 13.4% 10.1% 2021 12 15
185 2021
2021 12 31
2021 12 31 75.2
42
2021 12 31
2021 12 31
2021 12 31 8,000 2020 12 31 5,100
2021 12 31 10 2020 663.8
2021 186
2021 12 31 7.2
2020 12 31 8.1
145.8 2020 12 31
148.6
2021 12 31 2020 12 31
2021 12 31
187 2021
12
2022 4 20
54
59
Anthony C. Hooper 67
65
Margaret Han Dugan 65
Donald W. Glazer 77
Michael Goller 47
Ranjeev Krishana 48
Thomas Malley 53
Alessandro Riva 61
Corazon (Corsee) D. Sanders 65
50
54 2010 10
2005 2009 BioDuro, LLC Pharmaceutical Product
Development Inc. 2002 2004 Galenea Corp.
1998 2002 Telephia, Inc. 2007 (The Nielsen
Company) 1997 1998 Genta Incorporated
(McKinsey & Company)
1990 6 1996 1
2021 188
59 2016 2 2011
2003 2010
2020 1997 2010
Howard Hughes Medical Institute 2001 2010
George L. MacGregor 2004 Joyant
Pharmaceuticals, Inc.
2197 1984 7
1991 5
2004 2013
Anthony C. Hooper 67 2020 1 Hooper 2020 1
2018 9 2020 1 2011 2018 8
2010 2011 Hooper Bristol Myers Squibb Company (BMS)
2009 2010 Hooper BMS 2004
2009 Hooper BMS Hooper BMS
BMS Hooper Hooper
1978 1988 MBA Hooper MannKind Corporation
MNKD Hooper Hooper
189 2021
65 2016 2 2019 1
2018 1 2018 11
2018 6 2016 1 2018 3 Asia Pacific Telecom
2012 11 2015 12
(Telstra International Group) Telstra Autohome
2012 4 2012
11 Telstra Corporation Limited 2010
10 2013 10
GL Capital Group 2007 2010
2003 2007 2001 2003
2000 2001
21CN 2000
1991 8
1982 6
Margaret Han Dugan 65 2022 2 1 Dugan Dracen
2018 Dracen 20
Dugan
American Cyanamid Dugan
Dugan
2021 190
Donald W. Glazer 77 2013 2 2000 Glazer GMO
Trust 2005 GMO Trust Glazer Provant,
Inc. 2002 2010 1992
1995 Glazer Mugar/Glazer Holdings 1992 1993
WHDH-TV, Inc. 1997 Glazer Goodwin Procter LLP
1970 1978 Ropes & Gray LLP 1978 1992
Ropes & Gray 1978 1991
Provant, Inc. Glazer Environics Inc.
Kronos Incorporated Reflective Technologies, Inc. Teleco Oilfield Services Inc.
Glazer 1966 6 1969 6
1970 5
Glazer Glazer and FitzGibbon on Legal Opinions
Massachusetts Corporation Law& Practice Glazer
Michael Goller 47 2015 4 Goller Baker Brothers Investments
2005 Baker Brothers Goller 1999 2003 JPMorgan Partners,
LLC 1997 1999 Goller (Merrill
Lynch and Co.) Goller DBV Technologies SA
2017 2019 Levo Therapeutics, Inc. Goller 1997
5 2005 5
Goller
Ranjeev Krishana 48 2014 10 2020 2
Krishana 2011 Baker Bros. Advisors LP Baker Bros
Krishana (Pfizer, Inc.)
Krishana 2003 2007 2008 2011
2008 2010 Krishana Krishana
Accenture plc Krishana 1995 5
2001 6 Krishana
191 2021
Thomas Malley 53 2016 1 2007 5 Malley
Mossrock Capital, LLC 1991 4 2007 5 Malley Janus Mutual
Funds 1999 1 2007 5 Malley Janus Global Life
Sciences Fund Janus 1991 1998 Malley
Janus Malley 1991 6
Malley Kura Oncology, Inc.
2015 Kiniksa Pharmaceuticals, Ltd. 2016
OvaScience Inc. 2018 12 Millendo Therapeutics, Inc.
2012 2017 Synageva BioPharma Corp. 2015 5
2006 2015 Puma Biotechnology, Inc.
2011 2015 Cougar Biotechnology, Inc. 2009 7
2007 2009 Malley
Corazon (Corsee) D. Sanders 65 2020 8 Sanders
(Bristol Myers Squibb Corporation) 2019 11
2020 2 Sanders 2018 3 2019 11
2017 1 2018 3 Juno Therapeutics
1994 2017
Sanders Genentech Genentech (Late Stage
Portfolio Committee) Genentech (Late Stage Clinical Operations)
Genentech Genentech Genentech DATA
Sanders (Fred Hutchinson Cancer
Research Center) (Board of Trustees)
Molecular Templates Inc. MTEM Legend Biotech Corporation LEGN
AltruBio Inc. AbGenomics Ultragenyx Pharmaceutical Inc.
RARE Sanders (Magna Cum Laude)
Sanders
2021 192
Alessandro Riva 61 2022 2 1 Riva Intima
Bioscience, Inc. 2019 2021
Ichnos Sciences
2017 2019 Riva
Kite Pharma
2005 2016 Riva
GSK
Riva Century Therapeutics, Inc.
iPSC NK T Farmitalia Carlo Erba Rhne-Poulenc Rorer
Aventis (BCIRG) (CIRG)
Riva
Riva
50 2014 10 (Hillhouse Capital)
2005
1995 7 2003 5
2022 4 20
60
* 51
45
* 2021 6 30
** 2022 3 2 2022 4 3
193 2021
60 2018 4 2021 4 1
25 17
2018 4 2009 2018 4
2017 2018 4 (Pfizer Essential Health)
2004 2009 2001 2004
1992
2008 2018 (RDPAC)
(NDPE)
2017 2017
2017 1993 4 1990 1
51 2021 6 2020 6
2018 2020 (Alexion
Pharmaceuticals) 50
2015 2018 (Quest Diagnostics)
2007 2012 Johnson &
Johnson (J&J)
(Xian-Janssen) (PepsiCo) 1999
(Duke University) (Fuqua School of Business) 1992
45 2021 4 2011 5
20 10
Joyant Pharmaceuticals 1996
2001
2021 194
13.51(B)(1)
2020 12 31
13.51(B)(1)
Corazon (Corsee) D. Sanders 2021 2 24
2021 2 24
Anthony C. Hooper 2021 2 24
2022 1 31
2020 2 26 2021 2 24
195 2021
2021 12 31
2010 10 28 2018
8 8 06160 2016 2 3
BGNE 2021 12 15
688235
EUSA Pharma
ociperlimab
3 16
198
2021 12 31
1
2021 196
152
2021 12 31 280
2021 12 31 73.6%
26.0% 2021 12 31
2020 12 31
82.6% 38.7%
2021 2020 12 31 29.4% 45.3%
16.2% 21.8%
2021 12 31 5%
2021 12 31
197 2021
2022 1 31 2022 2 1 11 12
2022 2 1 Margaret Han Dugan Alessandro Riva
2022 2 1 Dugan
Riva
2022 2 25 Dugan
2021 198
199 2021
2021 200
10-K
2020 1 2
174.85 15,895,001 206,635,013
20.5% 2,779,241,000 (a) 2019 10 30
30 36% (b)
1.00 7.84 2019 10 31
26% (c) 2019 10 31 26%
201 2021
2019 11 29
2021 12 31
2021
2020 2021 12 31
12 31 12 31
(%)
(a)
2,779,241 100% 1,095,499 1,869,643 909,598
(a) 2019 11 29
12.5
2025
2019 11 1 2019 12 9 2020 1 3
2020 9 24
20.6%
20.4%
75,000,000
90
2020 12 1 (a)
20% (b) 60 (c)
2021 202
2020 3 18 2020 9 25 2020 10
9
2021 9 165,529
2,151,877 50,000,000 2021 12 31
50,000,000
7
2020 7 15 2020
202,995,338 2020 7 12
14.2308 185 145,838,979
20.8
(a)
(b)
(c)
(d)
2020 7 13 2020 7 16
2021 12 31 10.9 9.8
203 2021
2021 12 15 2021 6 16
2021
192.60
234.89 391.68 115,055,260
3,392,616,000
(i) (ii) (iii) (iv)
(v)
2020 11 16 2021 1 29 2021 4 20 2021 5 14
2021 6 1 2021 6 21 2021 6 28 2021 6 30 2021 7 9 2021 7 28
2021 10 15 2021 11 16 2021 11 23 2021 11 24 2021 11 29
2021 11 30 2021 12 2 2021 12 6 2021 12 7 2021 12 13 2021 12
21 2021 12 28 2021 4 30
2021 12 31 34
2021 204
2021 12 31
2021 12 31 283
30 30
2021 12 31 10
2021 12 31 629.7 2020 518.7
2021 12 31 0.7 2020 0.7
2021 12 31
205 2021
2020 3 17
2020 9 24
20.6% 2021 9
165,529 2,151,877 50,000
2021 12 31
2021 12 31
Anthony C. Hooper
Margaret Han Dugan 1
Donald W. Glazer
Michael Goller
Ranjeev Krishana
Thomas Malley
Alessandro Riva 1
Corazon (Corsee) D. Sanders
(1) 2022 2 1 Margaret Han Dugan Alessandro Riva
* 2022 1 31
2021 206
2023
2024 2022
2022 Anthony C. Hooper
Ranjeev Krishana Margaret Han Dugan Alessandro Riva
2022 2
Margaret Han Dugan Alessandro Riva 2022
Margaret Han Dugan Alessandro Riva 2023
2021 12 31 3.13
Anthony C. Hooper
207 2021
2022 2 17
60,000 2021
2022 4 1 2021
60,000
25,000(1)
12,500
20,000(1)
10,000
15,000(1)
7,500
18,000(2)
9,000
18,000(2)
9,000
(1) 2021 2,500
(2) 2021 2,500
2021 208
400,000
400,000 2021
50% 50%
(i) 100% (ii)
100%
(i) (ii)
2016
2016
1,000,000
2019 2
2020 2021 12 31
18.9 21.2
25 26 27
209 2021
2017 4 25
800,000
100%
60
(i) (ii) (iii)
(iv)
(i) (ii) 12 (iii)
(iv) 20,000 (v)
2015 2017 20
20 12
24
18
2021 210
2010
2018 7 24 2018
2021 2 24 2021 1 1 2023 12 31
2021 2018
100,000
2021 2021 1 1 2023 12 31
30 2021
2022
27
2021 12 31
211 2021
2021 12 31
2021 12 31
2021 12 31
18
2021 12 31
8.10
2021 212
2021 12 31 XV
(a) XV 7 8
(b)
352 (c)
(1)
23,348,966(2) 1.75%
10,000,000(3) 0.75%
102,188 (4)
0.01%
7,727,927(5) 0.58%
29,439,115 (6)
2.21%
510,941 (7)
0.04%
545,597(8) 0.04%
1,584,167 (9)
0.12%
15,471,305 (10)
1.16%
172,372(11) 0.01%
4,253,998 (12)
0.32%
1,127,542(13) 0.08%
50 (14)
0.000004%
407,638 (15)
0.03%
Donald W. Glazer 3,099,445(16) 0.23%
Michael Goller 361,998 (17)
0.03%
Anthony C. Hooper 92,651 (18)
0.01%
Ranjeev Krishana 361,998(19) 0.03%
Thomas Malley 1,274,746 (20)
0.10%
Corazon (Corsee) D. Sanders 52,780(21) 0.004%
198,575(22) 0.01%
352,716 (23)
0.03%
213 2021
(1) 2021 12 31 1,331,466,887
(2) (1) 1,399,809 (2) 21,612,062
(3) 337,095
(3) Roth IRA PENSCO
(4) The John Oyler Legacy Trust
(5)
(6) Oyler Investment LLC
Oyler Investment LLC 99%
(7) The Oyler Family Legacy Trust
(8) 545,597
(9)
(10) (1) 5,660,698 (2) 9,748,058
(3) 62,549
(11)
(12) Wang Investment LLC Wang Investment LLC 99%
(13)
(14)
(15) (1) 399,838
(2) 7,800
2021 214
(16) (1)Glazer 2,746,729 (2) Glazer Glazer
344,916 (3) Glazer 7,800
(17) (1)Goller 9,282 (2) Goller Goller 344,916
(3) Goller 7,800
(18) (1) Hooper Hooper 84,851
(2) Hooper 7,800
(19) (1)Krishana 9,282 (2) Krishana Krishana
344,916 (3) Krishana 7,800
(20) (1)Malley 399,282 (2) Malley Malley
867,664 (3) Malley 7,800
(21) (1) Sanders Sanders 44,980
(2) Sanders 7,800
(22) (1) 190,775
(2) 7,800
(23) (1) 344,916
(2) 7,800
2021 12 31
(a) XV 7
8
(b) 352 (c)
215 2021
2021 12 31
XV 2 3
336
(1)
Amgen Inc. 246,269,426 18.50%
Julian C. Baker (2)
152,875,363 11.48%
Felix J. Baker(2) 152,875,363 11.48%
Baker Bros. Advisors (GP) LLC(2) 152,419,703 11.45%
Baker Bros. Advisors LP (2)
152,419,703 11.45%
Baker Brothers Life 139,823,423 10.50%
Sciences Capital, L.P.(2)
Gaoling Fund, L.P.(3) 129,433,059 9.72%
Hillhouse Capital Advisors, Ltd. (3)
133,587,655 10.03%
The Capital Group Companies, 103,974,393 7.81%
Inc. (5)
JPMorgan Chase & Co.(4) 11,433,347 0.86%
9,952,323(S) 0.75%(S)
1,656,684 0.12%
36,465(S) 0.003%(S)
886,447 0.07%
14,532 0.001%
88,526,135 6.65%
(S)
(1) 2021 12 31 1,331,466,887
(2) Julian C. Baker Felix J. Baker Baker Bros. Advisors (GP) LLC Baker Bros. Advisors (GP) LLC
Baker Bros. Advisors LP BBA BBA 667, L.P. Baker Brothers Life Sciences, L.P.
Baker Brothers Life Sciences Capital, L.P. Baker Brothers Life Sciences, L.P.
BBA Michael Goller Ranjeev Krishana
BBA
2021 216
Baker Brothers Life Sciences Capital, L.P. 2021 12 15 2021 12 15
140,543,649 Baker Brothers Life Sciences, L.P.
Julian C. Baker Felix J. Baker Baker Bros. Advisors (GP) LLC BBA 667, L.P.
11,152,058 Baker Brothers Life Sciences, L.P. 140,543,649 723,996
BBA Baker Brothers
Life Sciences Capital, L.P. Baker Brothers Life Sciences, L.P. 140,543,649 723,996
BBA
Julian C. Baker Felix J. Baker 270,868 FBB3 LLC
151,004
(3) (i) 133,587,655 Gaoling Fund, L.P. YHG Investment, L.P. (ii) 13,447,603 Hillhouse
BGN Holdings Limited Hillhouse Capital Adrisors, Ltd. YHG Investment, L.P.
Gaoling Fund, L.P. Hillhouse Capital Management, Ltd. Hillhouse Fund II, L.P.
Hillhouse Fund II, L.P. Hillhouse BGN Holdings Limited Hillhouse Capital
Adrisors, Ltd. Gaoling Fund, L.P. YHG Investment, L.P. 133,587,655
Hillhouse Capital Management, Ltd. Hillhouse BGN Holdings Limited 13,447,603
Hillhouse Fund II, L.P. Hillhouse BGN Holdings Limited
13,447,603
(4) (i) 13,037,674 Capital International, Inc. (ii) 623,415 Capital International Limited
(iii) 2,090,794 Capital International Sarl (iv) 86,161,42 Capital Research and
Management Company (v) 8,645 Capital Bank and Trust Company (vi) 2,052,440
Capital Group Private Client Services, Inc.
Capital Group International, Inc. Capital Research and Management Company Capital
International, Inc. Capital International Limited Capital International Sarl Capital Group Private Client
Services, Inc. Capital Group International, Inc. Capital Bank and Trust Company The Capital
Group Companies, Inc. Capital Research and Management Company
Capital Group International, Inc. Capital International, Inc. Capital International Limited Capital
International Sarl Capital Group Private Client Services, Inc. 17,804,323 The
Capital Group Companies, Inc. Capital Bank and Trust Company 8,645
Capital Research and Management Company The Capital Group Companies Inc.
The Capital Group Companies Inc. Capital Research and Management Company
103,965,748
(5) JPMorgan Chase & Co. 2021 12 16
JPMorgan Chase & Co. 102,715,610 10,131,330
88,529,432 567,315 323,028
2021 12 31
XV 2 3
336
217 2021
1. 2011
2011 4 15 2015 4 17 2011 2016
2 2 2016 2011 2011
2021 12 31 2011 240 2011
2011 5 20 2016 1 31 2011
0.01 1.85
2011 2018 7 30
2021 1 1 5,671,104 2011 2021 12
31 2,908,297 2011 2021 1 1 2021 12 31
2011
2021 2021
1 1 12 31
2011 5 20 (1)
10 0.01 88,235 – 88,231 4 –
2013 4 3 (1)
10 0.01 879,267 – – – 879,267
2015 6 29 (1)
10 0.50 500,000 – – – 500,000
Thomas Malley 2016 1 25 (2)
10 1.85 552,752 – – – 552,752
2015 6 29 (3)
10 0.50 831,000 – 830,999 – 1
2012 7 6 (4)
10 0.01 12 – – – 12
2013 4 3 (4)
10 0.01 103,778 – 103,766 – 12
2015 6 29 (4)
259,569 – 259,558 – 11
2011 5 20 10 0.01 2,456,491 – 1,473,654 6,595 976,242
2016 1 31 (4)
1.85
5,671,104 – 2,756,208 6,599 2,908,297
2021 218
(1) 20% 80% 20% 48
(2)
(3) 25% 2016 7 15 75% 25% 36
(4) 20%/25% 80%/75% 20%/25% 48/36
2. 2016
2018 11 7 2018 12 7 2016 2016
1 14 2016 2021 12 31 2016
50,886,939
3.82% 2022 4 19 2016 48,505,794
2022 4 19 3.64%
2016 2020 4 13 2020 6 17
2016 2016 2016
2016 57,200,000 2016
2030
2016
219 2021
2016
2016 2020 6 17
10% 2016
30%
2016
12
1%
10
2021 220
(i)
1/13 (ii)
1/13
2016
2016
2016 2030 4 13
2016
2021 12 31 2016 1,020
2016 2016 2 8 2021 12 31
2016 0.5 28.81
2016 19
2021 1 1 64,082,595 2016 2021 12
31 54,065,073 2016
221 2021
2021 2021
1 1 12 31
(1) (2)
2016 11 16 (3)
10 2.79 2.84 2,047,500 – – – 2,047,500
2017 9 27 (3)
10 6.73 7.70 935,000 – – – 935,000
2018 4 30 (3)
10 13.37 13.04 996,810 – – – 996,810
2018 6 26 (3)
10 12.70 12.34 1,310,088 – – – 1,310,088
2019 6 5 (3)
10 9.25 9.23 2,193,282 – – – 2,193,282
2020 6 17 (3)
10 13.33 13.42 1,821,976 – – – 1,821,976
2021 6 16 (3)
10 25.54 26.53 – 906,906 – – 906,906
2016 11 16 (3)
10 2.79 2.84 1,613,430 – – – 1,613,430
2017 9 27 (3)
10 6.73 7.70 750,000 – – – 750,000
2018 6 26 (3)
10 12.70 12.34 655,044 – – – 655,044
2019 6 5 (3)
10 9.25 9.23 747,708 – – – 747,708
2020 6 17 (3)
10 13.33 13.42 560,599 – – – 560,599
2021 6 16 (3)
10 25.54 26.53 – 241,839 – – 241,839
2021 222
2021 2021
1 1 12 31
(1) (2)
Anthony C. 2020 3 3 (5)
10 12.62 12.22 21,970 – – – 21,970
Hooper
2020 6 17 (5)
10 13.33 13.42 45,383 – – – 45,383
2021 6 16 (5)
10 25.54 26.53 – 17,498 – – 17,498
2016 2 8 (4)
10 2.61 27.05 2.42 266,926 – 78,000 – 188,926
2017 6 2 (5)
10 2.94 3.15 65,988 – – – 65,988
2018 6 6 (5)
10 15.73 16.15 17,442 – – – 17,442
2019 6 5 (5)
10 9.25 9.23 64,610 – – – 64,610
2020 6 17 (5)
10 13.33 13.42 45,383 – – – 45,383
2021 6 16 (5)
10 25.54 25.63 – 17,498 – – 17,498
Donald W. 2017 4 19 (4)
10 2.84 2.83 199,992 – – – 199,992
Glazer
2018 6 6 (5)
10 15.73 16.15 17,442 – – – 17,442
2019 6 5 (5)
10 9.25 9.23 64,610 – – – 64,610
2020 6 17 (5)
10 13.33 13.42 45,383 – – – 45,383
2021 6 16 (5)
10 25.54 25.63 – 17,498 – – 17,498
223 2021
2021 2021
1 1 12 31
(1) (2)
Michael 2017 4 19 (4)
10 2.84 2.83 199,992 – – – 199,992
Goller
2018 6 6 (5)
10 15.73 16.15 17,442 – – – 17,442
2019 6 5 (5)
10 9.25 9.23 64,610 – – – 64,610
2020 6 17 (5)
10 13.33 13.42 45,383 – – – 45,383
2021 6 16 (5)
10 25.54 25.63 – 17,498 – – 17,498
Ranjeev 2017 4 19 (4)
10 2.84 2.83 199,992 – – – 199,992
Krishana
2018 6 6 (5)
10 15.73 16.15 17,442 – – – 17,442
2019 6 5 (5)
10 9.25 9.23 64,610 – – – 64,610
2020 6 17 (5)
10 13.33 13.42 45,383 – – – 45,383
2021 6 16 (5)
10 25.54 25.63 – 17,498 – – 17,498
Thomas 2017 6 2 (5)
10 2.94 3.15 169,988 – – – 169,988
Malley
2018 6 6 (5)
10 15.73 16.15 17,442 – – – 17,442
2019 6 5 (5)
10 9.25 9.23 64,610 – – – 64,610
2020 6 17 (5)
10 13.33 13.42 45,383 – – – 45,383
2021 6 16 (5)
10 25.54 25.63 – 17,498 – – 17,498
2021 224
2021 2021
1 1 12 31
(1) (2)
Corazon D. 2020 8 24 (5)
10 18.50 18.26 27,482 – – – 27,482
Sanders
2021 6 16 (5)
10 25.54 25.63 – 17,498 – – 17,498
2018 4 1 (4)
10 12.92 12.72 63,290 – – – 63,290
2019 6 5 (5)
10 9.25 9.23 64,610 – – – 64,610
2020 6 17 (5)
10 13.33 13.42 45,383 – – – 45,383
2021 6 16 (5)
10 25.54 25.63 – 17,498 – – 17,498
2017 4 19 (4)
10 2.84 2.83 199,992 – – – 199,992
2018 6 6 (5)
10 15.73 16.15 17,442 – – – 17,442
2019 6 5 (5)
10 9.25 9.23 64,610 – – – 64,610
2020 6 17 (5)
10 13.33 13.42 45,383 – – – 45,383
2021 6 16 (5)
10 25.54 25.63 – 17,498 – – 17,498
2018 4 30 (6)
10 13.37 13.04 766,599 – – – 766,599
2019 6 5 (3)
10 9.25 9.23 797,550 – – – 797,550
2020 6 17 (3)
10 13.42 13.33 756,821 – – – 756,821
2021 6 16 (3)
10 25.54 25.63 – 483,678 – – 483,678
225 2021
2021 2021
1 1 12 31
(1) (2)
2020 6 30 10 14.55 14.66 104,754 – – – 104,754
2021 6 16 10 25.54 26.53 – 177,853 – – 177,853
2016 11 16 (3)
10 2.79 24.66 2.84 1,752,500 – 1,752,500 – –
2017 6 29 (3)
10 3.50 23.98 3.45 1,250,000 – 1,250,000 – –
2018 6 26 (3)
10 12.70 25.11 12.34 364,208 – 303,264 60,944 –
2019 6 5 (3)
10 9.25 26.76 9.23 558,285 – 325,520 232,765 –
2020 6 17 (3)
10 13.33 21.36 13.42 315,341 – 105,092 210,249 –
2016 7 13 (3)
10 2.27 23.63 2.29 824,993 – 591,045 – 233,948
2017 6 27 (3)
10 3.50 3.49 999,999 – – – 999,999
2018 6 26 (3)
10 12.70 12.34 364,208 – – – 364,208
2019 6 5 (3)
10 9.25 9.23 558,285 – – – 558,285
2020 6 17 (3)
10 13.33 13.42 525,564 – – – 525,564
2021 6 16 (3)
10 25.54 26.53 – 332,527 – – 332,527
2021 226
2021 2021
1 1 12 31
(1) (2)
2016 9 2 (3)
10 2.26 26.04 2.27 324,575 – 117,000 – 207,575
2017 6 27 (3)
10 3.50 3.49 850,465 – – – 850,465
2018 6 26 (3)
10 12.70 25.57 12.34 212,680 – 89,882 – 122,798
2019 6 5 (3)
10 9.25 27.34 9.23 462,579 – 251,303 – 211,276
2020 6 17 (3)
10 13.33 25.57 13.42 273,286 – 68,315 – 204,971
2021 6 16 (3)
10 25.54 26.53 – 157,196 – – 157,196
2016 7 13 (3)
10 2.27 24.43 2.29 3,705,717 – 442,858 24 3,262,835
2016 7 22 (3)
10 2.13 24.03 2.10 285,394 – 179,907 – 105,487
2016 7 22 (6)
10 2.13 24.81 2.10 1,538,927 – 547,703 9,899 981,325
2016 7 29 (3)
10 2.11 21.25 2.02 78 – 52 – 26
2016 8 9 (3)
10 2.04 25.94 2.10 55,552 – 55,549 3 –
2016 8 22 (3)
10 2.28 2.24 – – – – –
2016 9 12 (3)
10 2.33 26.92 2.42 3,468 – 3,458 10 –
227 2021
2021 2021
1 1 12 31
(1) (2)
2016 9 19 (3)
10 2.51 22.44 2.38 41,331 – 41,327 4 –
2016 9 26 (3)
10 2.35 22.34 2.27 2,097 – 2,093 4 –
2016 10 12 (3)
10 2.48 25.55 2.42 199,498 – 65,000 – 134,498
2016 10 12 (6)
10 2.48 2.42 1,020 – – – 1,020
2016 10 17 (3)
10 2.42 27.75 2.55 89,999 – 28,600 – 61,399
2016 11 1 (3)
10 2.56 2.57 – – – – –
2016 11 7 (3)
10 2.43 2.46 – – – – –
2016 11 8 (3)
10 2.46 2.51 – – – – –
2016 11 16 (3)
10 2.79 25.85 2.84 18,434 – 18,434 – –
2016 11 21 (3)
10 2.46 23.55 2.42 32,890 – 32,890 – –
2016 11 28 (3)
10 2.49 28.38 2.38 68,471 – 29,471 – 39,000
2016 11 30 (3)
10 2.43 2.44 1,274 – – – 1,274
2016 12 1 (3)
10 2.44 24.63 2.37 43,771 – 43,771 – –
2016 12 9 (3)
10 2.07 2.09 34,099 – – – 34,099
2017 1 3 (3)
10 2.34 26.92 2.39 39,039 – 22,074 – 16,965
2021 228
2021 2021
1 1 12 31
(1) (2)
2017 1 5 (3)
10 2.44 28.32 2.39 244,998 – 181,337 – 63,661
2017 1 9 (3)
10 2.37 26.75 2.43 184,496 – 26,000 – 158,496
2017 1 17 (3)
10 2.51 26.23 2.53 7,644 – 7,644 – –
2017 1 17 (6)
10 2.51 25.14 2.53 119,782 – 31,226 – 88,556
2017 1 23 (3)
10 2.46 24.59 2.49 157,040 – 48,165 – 108,875
2017 1 30 (3)
10 2.80 25.81 2.62 6,201 – 6,201 – –
2017 2 1 (3)
10 2.68 27.14 2.77 296,998 – 144,300 7,709 144,989
2017 2 6 (3)
10 2.76 27.02 2.76 53,001 – 20,800 – 32,201
2017 2 8 (3)
10 2.67 23.71 2.78 1,924 – 1,924 – –
2017 2 13 (3)
10 2.77 25.78 2.77 191,269 – 119,626 – 71,643
2017 2 27 (3)
10 2.97 26.37 2.93 67,418 – 67,418 – –
2017 3 6 (3)
10 3.14 24.91 3.06 28,613 – 28,613 – –
2017 3 13 (3)
10 3.08 3.02 142,701 – – – 142,701
2017 3 20 (3)
10 3.04 28.90 3.04 205,517 – 120,549 – 84,968
2017 3 27 (3)
10 2.79 23.30 2.79 82,498 – 82,498 – –
229 2021
2021 2021
1 1 12 31
(1) (2)
2017 3 31 (6)
10 2.81 24.55 2.82 197,366 – 88,062 23,621 85,683
2017 4 3 (3)
10 2.82 26.51 2.82 9,581 – 3,653 – 5,928
2017 4 10 (3)
10 2.86 24.90 2.91 39,962 – 39,962 – –
2017 4 11 (3)
10 2.91 28.43 2.95 22,022 – 12,480 9,542 –
2017 4 17 (3)
10 2.92 26.14 2.95 258,154 – 138,697 9,867 109,590
2017 4 24 (3)
10 2.82 24.07 2.89 88,257 – 88,257 – –
2017 4 26 (3)
10 3.01 26.25 3.09 73,177 – 73,177 – –
2017 5 1 (3)
10 3.14 27.07 3.13 731,380 – 197,782 2,353 531,245
2017 5 2 (6)
10 3.13 25.31 3.12 271,063 – 154,856 858 115,349
2017 5 3 (3)
10 3.12 25.59 3.12 31,239 – 19,240 – 11,999
2017 5 8 (3)
10 3.02 25.18 2.98 73,320 – 73,320 – –
2017 5 10 (3)
10 2.88 26.01 2.92 21,281 – 21,281 – –
2017 5 15 (3)
10 2.81 27.90 2.90 153,491 – 144,391 – 9,100
2017 5 30 (3)
10 2.88 27.55 2.88 60,060 – 39,000 – 21,060
2017 6 1 (6)
10 2.83 27.16 2.94 1,230,593 – 72,748 7,800 1,150,045
2021 230
2021 2021
1 1 12 31
(1) (2)
2017 6 12 (3)
10 2.99 27.83 3.00 44,070 – 31,226 – 12,844
2017 6 14 (3)
10 3.04 25.70 3.05 1,138,475 – 349,115 12,779 776,581
2017 6 15 (6)
10 3.05 26.01 3.04 5,014,906 – 851,617 133,393 4,029,896
2017 6 21 (3)
10 3.31 26.08 3.45 39,234 – 21,450 – 17,784
2017 6 23 (3)
10 3.41 3.45 – – – – –
2017 6 27 (3)
10 3.50 27.20 3.49 2,692,170 – 458,861 – 2,233,309
2017 6 29 (3)
10 3.50 24.24 3.45 50,323 – 6,669 – 43,654
2017 7 10 (3)
10 5.40 26.94 5.45 216,229 – 59,605 – 156,624
2017 7 17 (3)
10 5.67 27.08 4.19 81,874 – 40,768 – 41,106
2017 7 17 (6)
10 5.67 26.24 4.19 469,677 – 103,311 – 366,366
2017 7 24 (3)
10 5.95 25.96 5.65 2,340 – 2,340 – –
2017 7 31 (3)
10 5.58 27.25 5.42 158,574 – 39,000 – 119,574
2017 7 31 (6)
10 5.58 27.00 5.42 476,710 – 103,402 2,236 371,072
2017 8 1 (3)
10 5.42 23.11 5.58 845,000 – 371,800 – 473,200
2017 8 2 (6)
10 5.58 24.17 5.45 83,460 – 46,592 36,868 –
231 2021
2021 2021
1 1 12 31
(1) (2)
2017 8 3 (3)
10 5.45 5.51 19,994 – – – 19,994
2017 8 7 (3)
10 5.56 26.83 5.95 318,747 – 204,438 – 114,309
2017 8 8 (3)
10 5.95 6.03 12,649 – – – 12,649
2017 8 10 (3)
10 5.95 27.35 5.59 31,356 – 31,356 – –
2017 8 11 (3)
10 5.59 5.46 – – – – –
2017 8 17 (3)
10 5.39 27.61 5.32 77,870 – 59,553 – 18,317
2017 8 25 (3)
10 5.38 5.29 – – – – –
2017 8 28 (3)
10 5.29 22.88 5.28 34,463 – 10,296 – 24,167
2017 8 31 (3)
10 5.30 25.67 5.30 – – – – –
2017 8 31 (6)
10 5.30 25.19 5.30 367,744 – 72,748 13,754 281,242
2017 9 5 (3)
10 5.78 23.46 5.68 282,867 – 12,870 – 269,997
2017 9 12 (3)
10 5.39 25.15 5.43 20,722 – 6,864 13,858 –
2017 9 13 (3)
10 5.43 5.82 – – – – –
2017 9 18 (3)
10 6.22 27.31 6.37 26,169 – 3,900 – 22,269
2017 9 22 (3)
10 6.53 28.36 6.55 187,005 – 96,850 – 90,155
2021 232
2021 2021
1 1 12 31
(1) (2)
2017 9 25 (3)
10 6.55 26.65 6.56 180,869 – 27,300 – 153,569
2017 9 26 (3)
10 6.56 24.78 8.71 62,751 – 62,751 – –
2017 9 29 (3)
10 7.49 26.80 7.96 199,992 – 162,500 – 37,492
2017 11 1 (3)
10 7.10 27.00 6.84 284,310 – 50,414 7,540 226,356
2017 11 30 (3)
10 6.38 27.28 6.15 36,231 – 17,277 8,190 10,764
2018 1 5 (3)
10 7.72 24.87 7.58 112,788 – 93,717 – 19,071
2018 1 31 (3)
10 9.52 27.04 10.44 111,490 – 27,105 – 84,385
2018 2 28 (3)
10 11.61 26.95 11.04 32,604 – 24,700 – 7,904
2018 4 30 (3)
10 13.37 26.01 13.04 38,727 – 21,320 – 17,407
2018 6 26 (3)
10 12.70 24.37 12.34 1,584,726 – 600,288 48,477 935,961
2018 6 29 (3)
10 11.90 25.53 11.83 32,214 – 20,111 – 12,103
2018 8 31 (3)
10 13.67 25.00 13.66 21,203 – 7,462 – 13,741
2018 8 31 (7)
10 13.67 13.66 108,537 – – – 108,537
2018 9 28 (3)
10 13.28 13.25 65,433 – – – 65,433
2018 9 28 (8)
10 13.28 13.25 39,260 – – – 39,260
233 2021
2021 2021
1 1 12 31
(1) (2)
2018 11 30 (3)
10 11.07 27.08 11.79 43,827 – 32,799 – 11,028
2018 12 31 (3)
10 10.53 25.47 10.79 287,157 – 110,539 32,565 144,053
2018 12 31 (8)
10 10.53 26.10 10.79 47,996 – 35,269 – 12,727
2019 1 25 (3)
10 9.62 25.22 10.44 73,021 – 34,372 – 38,649
2019 2 28 (3)
10 10.77 29.63 10.54 222,326 – 91,572 – 130,754
2019 3 5 (3)
10 11.68 26.84 11.51 98,735 – 20,241 – 78,494
2019 5 10 (3)
10 9.33 10.32 44,213 – – – 44,213
2019 6 5 (3)
10 9.25 25.53 9.23 4,162,067 – 850,265 237,640 3,074,162
2019 6 28 (3)
10 9.67 23.26 9.53 155,584 – 53,417 63,453 38,714
2019 8 30 (3)
10 11.14 25.23 11.06 138,476 – 41,275 – 97,201
2019 11 29 (3)
10 15.71 15.83 39,221 – – – 39,221
2019 12 31 (3)
10 12.80 25.47 12.92 54,431 – 24,908 – 29,523
2020 3 3 (3)
10 12.62 26.27 12.19 36,244 – 15,587 – 20,657
2020 3 31 (3)
10 9.65 29.63 9.67 404,235 – 109,460 – 294,775
2020 5 12 (3)
10 12.56 12.18 38,597 – – – 38,597
2021 234
2021 2021
1 1 12 31
(1) (2)
2020 5 29 (3)
10 12.49 12.73 21,281 – – – 21,281
2020 6 17 (3)
10 13.33 26.01 13.42 2,880,566 – 453,505 206,921 2,220,140
2020 6 30 (3)
10 14.55 14.66 212,771 – – – 212,771
2020 8 7 (3)
10 17.24 16.99 40,248 – – – 40,248
2020 8 31 (3)
10 18.69 18.85 14,040 – – – 14,040
2020 9 30 (3)
10 21.65 22.03 8,021 – – – 8,021
2020 11 6 (3)
10 23.08 23.07 175,708 – – – 175,708
2020 11 30 (3)
10 21.99 20.99 33,319 – – 6,357 26,962
2021 1 22 (3)
10 27.46 28.81 – 64,441 – – 64,441
2021 2 26 (3)
10 25.36 25.81 – 6,331 – – 6,331
2021 3 31 (3)
10 25.61 26.78 – 158,834 – – 158,834
2021 5 7 (3)
10 24.15 24.78 – 84,240 – – 84,240
2021 5 28 (3)
10 27.00 27.58 – 121,485 – – 121,485
2021 6 16 (3)
10 25.54 26.53 – 2,714,413 – 380,458 2,333,955
2021 6 30 (3)
10 27.48 27.28 – 88,829 – – 88,829
235 2021
2021 2021
1 1 12 31
(1) (2)
2021 8 6 (3)
10 25.84 25.61 – 164,151 – 5,889 158,262
2021 8 31 (3)
10 23.22 23.72 – 153,322 – – 153,322
2021 9 30 (3)
10 27.81 28.73 – 61,230 – – 61,230
2021 11 5 (3)
10 28.38 28.08 – 45,786 – – 45,786
2021 11 30 (3)
10 26.40 26.85 – 64,649 – – 64,649
2021 12 31 (3)
10 21.03 20.84 – 59,332 – – 59,332
64,082,595 6,244,524 14,471,093 1,790,953 54,065,073
(1) 13
(2) 13
(3) 25%
75% 25% 36
(4)
(5)
(6) 20% 80% 20% 48
2021 236
(7) 48
(8)
2016
2021 6 16 2021 4 20
2021 6 16 2021
11,250
3,000 Anthony
C.Hooper Donald W. Glazer Michael Goller Ranjeev Krishana
Thomas Malley Corazon (Corsee) D. Sanders 600
255,450
3. 2018
2018 11 7 2018 12 7 2018
2018 6 6 2018 2019 6 5 2018
2021 6 2018
2021 9 1 2018
2021 12 31 2,160,769 2018
2018 15%
2018 2018
2018 2018 5%
237 2021
2018
1% 10% 25,000
3 1 9 1
85%
2018
4. 2018
2018 6 6 2018 12,000,000
2018
2018 8 7 2018
2021 12 31 2018 2018
2018 8 31 2018 13.66
2021 12 31 2018 9,334,659
0.7% 2022 4 19 2018
9,366,629 2022 4 19 0.7%
2018 19
2021 238
2021 1 1 37,453 2018 2021 12 31
30,901 2018
2021 2021
1 1 12 31
(1) (2)
2018 8 31 (3)
10 13.67 25.49 13.66 37,453 – 6,552 – 30,901
37,453 – 6,552 – 30,901
(1) 13
(2) 13
(3) 25%
75% 25% 36
2018
5635(c)(4)
2018
239 2021
2018 12,000,000
2018
2018
2018
12
1%
10
(i)
1/13 (ii)
1/13
2018
2021 240
21 2021 12 15
115,055,260
Thomas Malley Anthony C. Hooper Corazon
(Corsee) D. Sanders Thomas Malley Corazon (Corsee) D. Sanders
Anthony C. Hooper Thomas Malley
2021 12 31
241 2021
13.20 13.21 13.22
2022 4 20
2018 8 8 2021
2022
2022 3 23
Ernst & Young LLP
2022 12 31
2022 4 20
2021 242
2021 12 31
2021
A.2.1 2022 1 1 C.2.1
Ranjeev Krishana
243 2021
3.21 C.3.3 C.3.7
Thomas Malley
Corazon (Corsee) D. Sanders Anthony C. Hooper Thomas
Malley 3.10(2) 3.21
3.25 B.1.2
Ranjeev Krishana
A.5.2
Donald W. Glazer Michael Goller
Alessandro Riva Anthony C. Hooper Donald W. Glazer
2021 244
2021 12 31
B.8
Scott A. Samuels
Scott A. Samuels
2021 1 1
245 2021
2021 1 1
Anthony C. Hooper
Margaret Han Dugan
Donald W. Glazer
Michael Goller
Ranjeev Krishana
Thomas Malley
Corazon (Corsee) D. Sanders
Alessandro Riva
2021
3.13
2021 246
A.4.1 2022 1 1
A.4.2 2022 1 1
2023 2024
2022
247 2021
2021 248
10-K
Thomas Malley Anthony C. Hooper Corazon (Corsee) D.
Sanders Thomas Malley Corazon (Corsee) D. Sanders Anthony C.
Hooper Thomas Malley 3.10(2) 3.21
Corazon (Corsee) D. Sanders 3.10(2)
3.21
2021 12 31
256
www.beigene.com HKEX investors 2021
2020 2021 2021
249 2021
Ranjeev Krishana
2021 12 31 25
35,000,000 85,000,000
2021 250
2021 12 31 256
www.beigene.com HKEX
investors 2021
Donald W. Glazer Michael Goller Anthony C. Hooper
Alessandro Riva Donald W. Glazer 2021 2 24
Anthony C. Hooper 2022 1 31
2021 2 1
Alessandro Riva
251 2021
2021 12 31
256
www.beigene.com
HKEX investors 2021
2021
3.13
2020 12 31
256 Margaret
Han Dugan Michael Goller Thomas Malley Alessandro Riva Corazon (Corsee) D.
Sanders Corazon (Corsee) D. Sanders
www.beigene.com
HKEX investors
2021 252
2020 2 26 2021 2 24
2021 12 31
256
Anthony C. Hooper Margaret Han Dugan Ranjeev Krishana Corazon
(Corsee) D. Sanders Anthony C. Hooper
www.beigene.com
HKEX investors
253 2021
www.beigene.
com HKEX investors
2021
2021 254
(Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana
Bay,Grand Cayman KY1-1108, Cayman Islands (a) (b)
1934 14a-8(b)(2)
(c)
(d) (e)
(f) (i) (ii)
(g)
D.3.1 2022 1 1 A.2.1
255 2021
2021 12 31 (1)
9/9 1/1
Anthony C. Hooper (3)
9/9 12/12 3/3 5/5 1/1
9/9 3/4 1/1
9/9 6/7 5/5 1/1
Donald W. Glazer 9/9 3/3 1/1
Michael Goller 9/9 3/3 4/4 1/1
Ranjeev Krishana 9/9 7/7 5/5 1/1
Thomas Malley 9/9 12/12 4/4 1/1
Corazon (Corsee) D.
Sanders (2)
9/9 11/12 4/4 3/5 1/1
(3)(4)
8/9 3/3 5/5 1/1
9/9 6/7 4/4 1/1
(1) 2022 2 1 Margaret Han Dugan Alessandro Riva Dugan
Riva 2022
2 25 Dugan
(2) 2021 2 24 Sanders
(3) 2021 2 24 Anthony C. Hooper
(4) 2022 1 31
2021 256
A.2.7 2022 1 1 C.2.7 2021
12 31
2021 12 31
2021 12 31
257 2021
2021 12 31
2022 2 1 Margaret Han Dugan Alessandro Riva 2022 1
Dugan Riva
2021 2020 12 31
2021 2020
7,227 3,811
– 97
7,227 3,908
2021 2021
2021
2021 10-Q
2020
2021 258
2019 10 31 2020
1 2
20.5% 14A
14A
12.5
LUMAKRAS
(sotorasib)
259 2021
LUMAKRAS (sotorasib)
14A.52
14A.53(1)
14A.52 14A.53(1)
(a) 14A
(b)
(c)
(d)
14A.55 14A.56
(e) 2019 11 1
2021 260
(a)
= 50% x
(b)
(i) (ii) (iii)
(x) (y)
20
LUMAKRAS (sotorasib)
= x
= x
261 2021
12.5
1,250 3,750
(a) (b) (c)
14A.56
3000 740
2021 12 31
2021 12 31
(a)
(b)
(c)
2021 262
2020 3 17
2020 9 24
20.6%
20.4% (i)
(ii)
2020 12 1 (a)
20% (b) 60
(c)2023 12 1
2020 3 18 2020 9 25 2020 10
9
2021 9 165,529
2,151,877 50,000
263 2021
2020 9 24
73,640,000 500,000,000 14,728,000 100,000,000
58,912,000 400,000,000
200,000,000 (i)2021 11 9
(ii) 2021 10 8
(i)2022 11 9
(ii)
14A 15
2021 12 31 14A.71
2,069,546
399.43 137
15
10
2021 12 31 27
14A
2021 264
Committee of Sponsoring Organizations of the Treadway Commission
2013
404
265 2021
2021 266
(i) (ii)
267 2021
2021 12 31
D.2.3
Scott A.
Samuels 2021 12 31 3.29
61 62
21
21
21
2021 268
(Mourant
Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman KY1-
1108,Cayman Islands
(Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana
Bay, Grand Cayman KY1-1108, Cayman Islands [ ]
2022
2016 2 8 2021 6 16
2021 4 30
(www.hkexnews.hk)
2021 12 15
269 2021
1933
2021 270
277 381
2021 12 31
2021 12 31
271 2021
2021 12 31
1,459.2 2021 12 31
213.9
2
2021 272
2 3
Novartis Pharma AG
2021 12 31 538.1
2021 12 31 111.9
606
606
1)
PD-1 2
650.0
PD-1
PD-1
273 2021
2021 274
275 2021
2022 3 30
2021 276
12 31
2021 2020
4,375,678 1,381,950
4 328 307
5 2,241,962 3,268,725
6 483,113 60,403
7 242,626 89,293
13 270,173 160,012
7,613,880 4,960,690
4 6,881 7,748
10 587,605 357,686
9 117,431 90,581
11 46,679 5,000
12 110,424 65,962
13 163,049 113,090
1,032,069 640,067
8,645,949 5,600,757
14 262,400 231,957
13 558,055 346,144
3 187,414 –
12 21,395 20,380
9 21,925 13,895
3 120,801 127,808
15 427,565 335,015
1,599,555 1,075,199
277 2021
12 31
2021 2020
15 202,113 183,637
3 220,289 –
9 43,041 29,417
12 14,169 10,792
3 269,561 375,040
13 54,234 57,429
803,407 656,315
2,402,962 1,731,514
24
0.0001
9,500,000,000 2021
2020 12 31
1,334,804,281 1,190,821,941 133 118
11,191,007 7,414,932
20 17,950 6,942
(4,966,103) (3,552,749)
6,242,987 3,869,243
8,645,949 5,600,757
2021 278
12 31
2021 2020
16 633,987 308,874
3 542,296 –
1,176,283 308,874
164,906 70,657
1,459,239 1,294,877
990,123 600,176
11 750 846
2,615,018 1,966,556
(1,438,735) (1,657,682)
(15,757) 1,998
5 15,904 37,490
(1,438,588) (1,618,194)
12 (25,234) (17,671)
(1,413,354) (1,600,523)
– (3,617)
(1,413,354) (1,596,906)
18 (1.17) (1.47)
18 1,206,210,049 1,085,131,783
(15.23) (19.13)
92,785,388 83,471,676
279 2021
12 31
2021 2020
(1,413,354) (1,600,523)
20 13,714 23,603
23 1,865 (8,113)
20 (4,571) (419)
(1,402,346) (1,585,452)
– (3,489)
(1,402,346) (1,581,963)
2021 280
12 31
2021 2020
(1,413,354) (1,600,523)
46,457 31,789
19 240,712 183,481
83,500 109,500
3 (112,486) (113,986)
5 (7,632) (11,826)
(41,085) (27,807)
23,510 (4,673)
(423,019) 10,363
(153,333) (58,906)
(107,128) (56,217)
20,008 95,835
140,044 185,012
407,703 –
(2,620) (25,503)
(1,298,723) (1,283,461)
(262,942) (117,508)
(2,147,881) (5,663,727)
3,146,891 2,751,075
(8,500) (109,500)
(43,409) –
(43,500) (26,681)
– (2,025)
640,659 (3,168,366)
281 2021
12 31
2021 2020
20 3,392,616 –
20 50,000 4,232,017
3 – 616,834
8 – (28,723)
15 16,838 110,208
15 – (132,061)
15 406,449 323,697
15 (321,754) (12,247)
92,762 93,101
3,636,911 5,202,826
14,035 18,231
2,992,882 769,230
1,390,005 620,775
4,382,887 1,390,005
4,375,678 1,381,950
328 307
6,881 7,748
15,695 10,596
29,967 44,130
53,197 42,762
75,000 –
2021 282
2019 12 31 801,340,698 79 2,925,970 (8,001) (1,955,843) 962,205 16,150 978,355
145,838,979 14 2,069,596 – – 2,069,610 – 2,069,610
206,635,013 21 2,162,386 – – 2,162,407 – 2,162,407
38,020,892 3 93,098 – – 93,101 – 93,101
(1,013,641) 1 – – – 1 – 1
– – 183,481 – – 183,481 – 183,481
– – – – – – (3,545) (3,545)
– – (19,599) – – (19,599) (9,116) (28,715)
– – – 14,943 – 14,943 128 15,071
– – – – (1,596,906) (1,596,906) (3,617) (1,600,523)
2020 12 31 1,190,821,941 118 7,414,932 6,942 (3,552,749) 3,869,243 – 3,869,243
115,055,260 12 3,392,604 – – 3,392,616 – 3,392,616
2,151,877 – 50,000 – – 50,000 – 50,000
28,778,893 3 92,759 – – 92,762 – 92,762
(2,003,690) – – – – – – –
– – 240,712 – – 240,712 – 240,712
– – – 11,008 – 11,008 – 11,008
– – – – (1,413,354) (1,413,354) – (1,413,354)
2021 12 31 1,334,804,281 133 11,191,007 17,950 (4,966,103) 6,242,987 – 6,242,987
283 2021
1.
BTK
PD-1
PARP1
PARP2
13
2,200 30 90
30
3 14,500
2010 23
8,000
2021 284
1.
2021 12 31 42
BeiGene 101 100%
BeiGene AUS Pty Ltd 56,947,230 100%
BeiGene Australia
* 46,711,000 100%
* 5,050,000,000 100%
BeiGene (Canada) ULC 100 100%
BeiGene ESP, S.L. 3,000 100%
BeiGene France Sarl 7,500 100%
* 3,870,000,000 100%
* 263,000,000 100%
BeiGene Germany GmbH 25,000 100%
BeiGene (Hong Kong) Co., Limited 1 100%
* 4,000,000 100%
BeiGene International GmbH 20,000 100%
BeiGene (Italy) Sarl 10,000 100%
BeiGene Brazil Ltda. 50,000 100%
BeiGene Poland sp. z o.o. 5,000 100%
BeiGene Sweden AB 25,000 100%
285 2021
1.
BeiGene Turkey Medical Products 10,000 100%
Trade Limited Company
BeiGene Ireland Limited – 100%
BeiGene Ireland
BeiGene Japan, Ltd. 1,781,660 100%
BeiGene Korea Y.H. 100,000,000 100%
BeiGene Netherlands B.V – 100%
BeiGene NZ Unlimited 100,000 100%
BeiGene NZ, Limited
BeiGene Pharmaceuticals GmbH 20,000 100%
* 3,800,000 100%
* 7,000,000 100%
* 1,000,000 100%
* 534,344,311 100%
* 70,000,000 100%
BeiGene Singapore Pte., Ltd. 1 100%
* 144,000,000 100%
BeiGene Switzerland GmbH 20,000 100%
BeiGene Switzerland
168,000,000 100%
BeiGene UK, Ltd. BeiGene UK 140 100%
BeiGene United Kingdom, Ltd. 100 100%
2021 286
1.
BeiGene USA, Inc. BeiGene USA 1 100%
BeiGene US Holdings, LLC – 100%
BeiGene US Manufacturing Co., Inc. 101,000,000 100%
BeiGene Hopewell Urban Renewal, LLC 75,000,000 100%
Pi Health, Ltd. 12,000,000 100%
Pi Health USA, LLC 5,000,000 100%
Newco 101 – 100%
*
2.
2020
MapKure,LLC MapKure
2020 6 MapKure
5 2020 11
8
287 2021
2.
830
2021 288
2.
289 2021
2.
2021 290
2.
20
3 10
3 5
3 5
2019 1 1 842 842
842-20-25 2021 12 31
291 2021
2.
12
842
2017
2019 2021
50
2018
36
2020
30
2021 292
2.
2021 2020 12 31
10
2021 2020 12 31
293 2021
2.
2021 2020 12 31
820 820
820
820
1
2
3
820 (1) (2) (3)
2021 294
2.
2021 2020 12 31
2021 12 31 1 2 3
107,855 – –
315,564 – –
5
2,241,962 – –
5
23,809 10,306 –
2,689,190 10,306 –
2020 12 31 1 2 3
286,072 – –
80,838 – –
5
3,268,725 – –
5
10,810 6,669 –
3,646,445 6,669 –
295 2021
2.
3
Leap Therapeutics, Inc Leap
2020 1 2021 9 Leap
Leap 1 Leap
2
5
2021 2020 12 31
2018 1 1 606
606
606
606
(i) (ii) (iii)
(iv) (v)
2021 296
2.
606
EUSA Pharma
100%
BRUKINSA
BRUKINSA
45 90
297 2021
2.
NRDL
808
808
808
808
606 808
606
2021 298
2.
299 2021
2.
(i) (ii)
(i) (ii)
(iii)
(iv) (v)
2021 300
2.
2021 2020 12 31
301 2021
2.
220
718 718
718
718
2021 302
2.
718 505
505-50
303 2021
2.
740
50%
260
2021 304
2.
280
2021 2020 12 31 4,375,678,000 1,381,950,000
2021 2020 12 31
2,241,962,000 3,268,725,000
2021 12 31
2021 2020 12 31 483,113,000 60,403,000
305 2021
2.
2021 12 31
26.0% 19.9% 16.7% 2021 12 31 23.4% 2021
12 31 2021
12 31 66.4% Ociperlimab
300,000,000
2020 12 31
38.7% 25.4% 2020 12 31 59.6%
2021 306
2.
1994 1 1
2005 7 21 2021
2020 12 31 2.3% 6.3%
307 2021
2.
2019 12 2019 12 740
740
2021 1 1
2021 11 2021 10 832
2021 12 15
2021 308
3.
2021 12 31
2021 2020 12 31
12 31
2021 2020
484,646 –
53,671 –
3,979 –
542,296 –
309 2021
3.
2021 1
650,000,000
1,300,000,000
250,000,000
606
(1)
(2)
(3)
2021 310
3.
606
650,000,000
484,646,000 165,354,000
2021 12 31
2021 12 31
2021 12 31 53,421,000
311 2021
3.
2021 12
TIGIT
5
2022 1 300,000,000
2023 2023 2023
600,000,000 700,000,000
745,000,000 1,150,000,000
50%
25%
606
(1)
(2) (3)
(4)
2021 312
3.
300,000,000
71,980,000
213,450,000
14,570,000
2021 12 31
3,979,000 250,000
313 2021
3.
2017 7 5
PD-1
PD-1
2017 8 31 PD-1 A&R
PD-1
A&R PD-1 2019 6 14
A&R PD-1 263,000,000
92,050,000 2017 170,950,000 2017 12
13,000,000 Celgene Holdings East
Corporation A&R PD-1
A&R PD-1
2021 314
3.
606 (a)
(b)
250,000,000
2019 6
150,000,000
ABRAXANE
2020 3 25 NMPA
ABRAXANE
2021 10 180 ABRAXANE
ABRAXANE ABRAXANE
ABRAXANE
315 2021
3.
2019 10
2020 1 2
2019
2020 11 2020 7
2020 12
B
2021 7
R/R
1,250,000,000
KRAS G12C LUMAKRAS (sotorasib)
LUMAKRAS
2021 316
3.
808 100%
2019 10 31
2020 1 2 174.85 15,895,001
20.5%
Anthony C. Hooper 2020 1
132.74
2,109,902,000
601,857,000
2,779,241,000
2,162,407,000 616,834,000
317 2021
3.
2020 12 31
2020
12 31
2,162,407
616,834
2,779,241
2021 2020 12 31
12 31
2021 2020
115,464 117,005
112,486 113,986
227,950 230,991
2021 318
3.
2021
12 31
791,059
2021 12 31 2020 12 31
12 31
2021 2020
120,801 127,808
269,561 375,040
390,362 502,848
2021 2020 12 31
12 31
2021 2020
1,893 (1,210)
(45,152) (9,750)
423 (660)
(42,836) (11,620)
319 2021
3.
2021 2020 12 31
110,303,000 38,392,000 2021 12 31 2020 12 31
106,790,000 122,828,000
2021 12 31 18.5%
14A 14A
2021 2020 12 31
12 31
2021 2020
83,500 109,500
15,000 15,800
43,394 –
141,894 125,300
2021 320
3.
Shoreline Biosciences, Inc.
2021 6 Shoreline Biosciences Inc. Shoreline Shoreline
iPSC
Shoreline
Shoreline Shoreline
Shoreline 2022 1
45,000,000
2021
12 31
2021 12
LBL-007 LBL-007
LAG-3 2022 1 30,000,000
742,000,000
2021 12 31
321 2021
3.
EUSA Pharma
2020 1 EUSA Pharma EUSA
β EUSA
EUSA
40,000,000 120,000,000
2020 12 31
2021
EUSA
Assembly Biosciences, Inc.
2020 7 Assembly Biosciences, Inc Assembly Assembly
Assembly ABI-H0731 ABI-H2158 ABI-H3733
Assembly
Assembly 40,000,000
503,750,000 Assembly
2020 12 31
2021 322
3.
2020 8
(BAT1706)
2020 9 10 2020 9 18
2020 10 20,000,000
145,000,000
2020 12 31 2021 11
Seagen, Inc.
2019 11 Seagen, Inc. Seattle Genetics, Inc.
Seagen Seagen
Seagen
Seagen 20,000,000
Seagen
2019 12 31
323 2021
3.
Zymeworks Inc.
2018 11 Zymeworks Zymeworks
HER2 ZW25(zanidatamab)
ZW49 Zymeworks
Zymeworks Azymetic EFECT
Zymeworks
zanidatamab ZW49 HER2
Zymeworks
zanidatamab ZW49
ZW49 zanidatamab Zymeworks 40,000,000
Zymeworks
zanidatamab ZW49
Azymetric EFECT Zymeworks 20,000,000
Zymeworks
2018 12 31
2021 2020 12 31 zanidatamab
2021 324
3.
2021 2020 12 31
4.
2021 12 31 2020 12 31 7,209,000 8,055,000
5.
2021 12 31
2,245,662 – 3,700 2,241,962
2,245,662 – 3,700 2,241,962
325 2021
5.
2020 12 31
3,267,875 850 – 3,268,725
3,267,875 850 – 3,268,725
2021 12 31 2021 12 31
2021
12 31
Leap Therapeutics, Inc. (Leap)
2020 1 Leap 5,000,000 Leap B
B 2020 3 Leap Leap
2021 9 Leap 7,250,000
Leap 2021 12 31 Leap
8.3% 13.1%
2021 2020 12
31 9,386,000 12,479,000
2021 326
5.
Leap Therapeutics, Inc. (Leap)
2021 12 31 2020 12 31
12 31
2021 2020
Leap 23,809 10,810
Leap 10,306 6,669
2021 12 31 2020 12 31
43,722,000 9,705,000 2021 2020 12 31
MapKure
2019 6 MapKure SpringWorks herapeutics, Inc.
SpringWorks BGB-3245 MapKure BGB-3245
B-RAF V600BRAF V600B-RAF RAF
MapKure10,000,000 A 71.4%
SpringWorks 3,500,000 A 25%
250,000 A 1.8%
MapKure
327 2021
5.
MapKure
2020 6 MapKure SpringWorks
A 55.6%
MapKure A 70%
2020 12 31 MapKure
MapKure 55.6% MapKure
11,307,000
10,000,000 MapKure 55.6%
2020 6 8 MapKure
2021 12 31 2020 12 31
1,176,000 491,000 2021 12 31 2020 12 31 MapKure
8,333,000 9,509,000
2020 7
11,782,000 80,000,000
60%
2021 12 31
19.3%
2021 2020 12 31
145,000 68,000 2021 12 31 2020 12 31
12,333,000 12,189,000
2021 328
5.
2021 2020 12 31
6.
12 31
2021 2020
483,528 60,515
(415) (112)
483,113 60,403
45 90
12 31
2021 2020
3 483,058 60,403
3 6 55 –
483,113 60,403
329 2021
6.
12 31
2021 2020
1 1 112 –
309 109
(6) 3
12 31 415 112
7.
12 31
2021 2020
78,140 19,330
9,397 1,378
155,089 68,585
242,626 89,293
2021 330
8.
(CTA)
(MAA)
2017 3
200,000,000
95%
100,000,000 5% 2017 3 7
900,000,000
2019 9
100%
95%
2020 9
5% 28,723,000 195,262,000
2020 11 9,116,000
100%
19,599,000
132,061,000 900,000,000 36,558,000
249,140,000
331 2021
8.
200,000,000
120,000,000 80,000,000
2020 10
80,000,000 118,320,000 2021
10 9 198,320,000 200,000,000
73,640,000 500,000,000 14,728,000
100,000,000 58,912,000 400,000,000
2021 12 31 15,693,000
100,000,000 15
9.
50 36 30
12
12 31
2021 2020
22,536 18,271
4,892 2,465
1,823 1,018
29,251 21,754
2021 332
9.
12 31
2021 2020
60,762 41,850
56,669 48,731
117,431 90,581
21,925 13,895
43,041 29,417
64,966 43,312
2022 12 31 24,225
2023 12 31 20,072
2024 12 31 16,103
2025 12 31 8,272
2026 12 31 1,546
70,218
(5,252)
64,966
333 2021
9.
12 31
2021 2020
19,962 17,571
37,454 17,634
12 31
2021 2020
3 3
5.15% 6.26%
10.
12 31
2021 2020
65,485 –
118,203 78,640
50,288 37,643
144,083 111,527
119,585 96,669
27,404 20,782
525,048 345,261
(124,286) (73,354)
186,843 85,779
587,605 357,686
2021 334
10.
2021 11 75,197,000 42
2021 12 31
2021 12 31 2020 12 31
12 31
2021 2020
90,229 48,824
63,361 29,858
17,178 4,507
16,075 2,590
186,843 85,779
2021 2020 12 31 44,742,000 30,943,000
11.
2021 12 31 2020 12 31
2021 12 31 2020 12 31
7,500 (3,250) 4,250 7,500 (2,500) 5,000
43,394 (965) 42,429 – – –
816 (816) – 816 (816) –
51,710 (5,031) 46,679 8,316 (3,316) 5,000
335 2021
11.
10 Merck KGaA
2018 12 31 EUSA Pharma
2018
9 2020 2
2024 2
13
12 31
2021 2020
965 –
750 846
1,715 846
2021 12 31
12 31
2022 3,314 750 4,064
2023 3,314 750 4,064
2024 3,314 750 4,064
2025 3,314 750 4,064
2026 3,314 750 4,064
2027 25,859 500 26,359
42,429 4,250 46,679
2021 336
12.
12 31
2021 2020
(606,752) (369,066)
34,923 33,608
(866,759) (1,282,736)
(1,438,588) (1,618,194)
12 31
2021 2020
15,252 16,121
(9) (5,678)
805 68
16,048 10,511
7,516 (1,152)
(47,094) (27,030)
(1,704) –
(41,282) (28,182)
(25,234) (17,671)
337 2021
12.
12 31
2021 2020
(1,438,588) (1,618,194)
25% 25%
(359,647) (404,549)
185,874 218,473
(2,826) 8,436
(27,411) (22,032)
– (3,827)
210,306 209,085
(31,530) (23,257)
(25,234) (17,671)
1.8% 1.1%
2021 338
12.
12 31
2021 2020
84,766 33,512
625,114 358,425
14,982 13,981
82,060 58,835
937,069 724,779
11,571 9,066
1,755,562 1,198,598
(1,647,985) (1,134,585)
107,577 64,013
(11,322) (8,843)
(11,322) (8,843)
96,255 55,170
2021 12 31
2021
2020 12 31 210,306,000 209,085,000
339 2021
12.
2021 2020 12 31 3,644,005,000 2,230,857,000
2021 12 31 2023 2031
942,541,000 2025 2028 2,325,359,000
351,645,000 88,632,000
2035 2041
2021 2020 12 31
12 31
2021 2020
1 1 7,123 4,633
2,802 2,497
– (7)
12 31 9,925 7,123
2021
12 31 12
2021 2020 12 31
2021
12 31 2013 2021 2011 2021
2018 2021 2015 2021
2011 2021
2021 340
12.
2022 2021
12 31 2,863,000 0.01
2021 2020 12 31
2021 12 31
1,844,000
13.
12 31
2021 2020
87,239 71,341
58,579 30,392
12,010 12,651
5,052 6,619
1,695 1,347
78,538 25,996
27,060 11,666
270,173 160,012
341 2021
13.
12 31
2021 2020
109 109
14,140 16,984
(1) 24,237 29,778
17,162 10,913
6,609 5,962
100,792 49,344
163,049 113,090
(1)
12 31
2021 2020
139,966 106,765
213,922 143,302
71,560 66,131
45,661 14,373
59,639 11,874
27,307 3,699
558,055 346,144
2021 342
13.
12 31
2021 2020
46,352 49,139
7,814 8,113
68 177
54,234 57,429
14.
2021 12 31 2020 12 31
12 31
2021 2020
3 257,977 230,638
3 6 3,210 312
6 1 1,110 147
1 103 860
262,400 231,957
343 2021
15.
2021 12 31 2020 12 31
12 31
2021 2020
2018/04/04 580,000 9 2027/04/04 (1) 1,255 8,000 307 2,000
2020/01/22 (2) 9 2029/01/20 (2) 1,569 10,000 – –
2020/09/24 200,000 (3) 4.5% 200,000 1,274,535 198,320 1,294,010
2020/09/24 500,000 (4) 4.5% 15,693 100,000 15,326 100,000
(5) 209,048 1,332,197 121,062 789,918
427,565 2,724,732 335,015 2,185,928
2018/04/04 580,000 9 2027/04/04 (1) 89,444 570,000 88,584 578,000
2020/01/22 (2) 9 2029/01/20 (2) 53,353 340,000 53,641 350,000
2020/11/09 378,000 9 2029/11/08 (6) 59,316 378,000 41,412 270,206
202,113 1,288,000 183,637 1,198,206
1. 2021 12 31 4.9%
2021 12 31 312,000 2,000,000
2. 2020 1 22
1,100,000,000
2020
12 31 1,100,000,000
350,000,000 2021 12 31 4.4%
2021 344
15.
3. 120,000,000 80,000,000
2021 10 8
2021 10 8 2022 10 9
2021 10 8 198,320,000
200,000,000
4. 100,000,000 400,000,000
(i)2021 11 9
(ii) 2021 10 8
(i) 2022 11 9 (ii)
Hillhouse Capital Hillhouse Capital
Hillhouse Capital
5. 2021 12 31 2020 12 31
1,940,000,000 2021 4 19 2022 12 15 2021
12 31 206,449,000 1,332,197,000 2021 12 31
123,122,000 789,918,000 2021 12 31
4.2%
6. 2021 12 31 4.3%
2021 12 31 16,838,000 107,794,000
345 2021
15.
2021 12 31
2022 12 31 427,565
2023 12 31 15,300
2024 12 31 31,832
2025 12 31 38,027
2026 12 31 42,726
74,228
629,678
2021 2020 12 31
29,263,000 18,309,000 1,054,000 338,000
16.
2021 2020 12 31
12 31
2021 2020
748,824 324,672
(114,837) (15,798)
633,987 308,874
2021 346
16.
2021 2020 12 31
12 31
2021 2020
255,119 163,358
217,987 41,702
70,065 47,372
19,591 29,975
ABRAXANE – 17,770
45,956 8,496
12,515 –
12,754 201
633,987 308,874
2021 2020 12 31
12 31
2021 2020
1 1 11,874 3,198
114,837 15,798
(67,072) (7,122)
12 31 59,639 11,874
2021 3 1
2022 1 1 2021 12 31
2021 12 31 57,450,000
347 2021
17.
12 31
2021 2020
164,906 70,657
10 44,742 30,943
1,459,239 1,294,877
9 22,536 18,271
11 1,715 846
3,821 2,642
720,551 466,962
240,712 183,481
38,810 13,372
1,000,073 663,815
(67) (1,492)
5,991 (4,813)
(13,528) (20,352)
106 9
2021 2020 12 31 463,441,000 346,203,000
2021 348
18.
12 31
2021 2020
(1,413,354) (1,600,523)
– (3,617)
(1,413,354) (1,596,906)
1,206,210,049 1,085,131,783
(1.17) (1.47)
2021 2020 12 31
2021 2020 12
31
349 2021
19.
2016
2016 1 2016
2016 2016 2 65,029,595 2016
2011 2011 2016
2011
2021 12 31 2011 2016
5,166,510 2016 2017 1 1
(i) (5)% (ii)
2018 1 1 29,603,616
2016 2018 8 2016
2018 12 2016 38,553,159
2020 6 2016
57,200,000 2030 4 13
2016
2021 12 31 2016 50,886,939
2021 350
19.
2018
2018 6 2018 2018 12,000,000
5635(c)(4) 5635(c)(4)
2018 2018
2016 2018
8 2018
2021 12 31 2018 9,344,659
2018
2018 6 2018 3,500,000
2018 8
2018 12 3,855,315
7,355,315 6
15%
10%
351 2021
19.
2018
1 2
ADS ADS
2021 8 31 425,386 308.30 23.72 262.06 20.16 8,575
2021 2 26 436,124 236.30 18.18 200.86 15.45 6,738
2020 8 31 485,069 164.06 12.62 139.45 10.73 5,203
2020 2 28 425,425 145.54 11.20 123.71 9.52 4,048
2019 8 30 233,194 143.75 11.06 122.19 9.40 2,192
2019 2 28 154,505 137.05 10.54 116.49 8.96 1,385
1
2
2021 12 31 5,194,546
10
2021 352
19.
2011 2016 2018
2019 12 31 108,417,254 3.96
8,999,536 13.54 7.15
(29,707,587) 2.82 416,509
(2,717,488) 7.22
2020 12 31 84,991,715 5.27
6,244,524 26.46 12.40
(17,233,853) 4.52 367,110
(1,797,498) 13.27
2021 12 31 72,204,888 7.08 5.81 1,026,958
2021 12 31 55,576,828 4.31 5.08 919,118
2021 12 31 70,043,242 6.79 5.73 1,012,938
2021 12 31 14,466,414 88,394,000
2.1
2021 2020 12 31 53,571,000
55,127,000
353 2021
19.
12 31
2021 2020
9.94 ~ 14.97 4.95 ~ 11.89
1.1% ~ 1.7% 0.6% ~ 1.1%
2.8 2.8
51% ~ 59% 58% ~ 59%
0% 0%
10 10
2021 354
19.
2016
2019 12 31 75,000 2.27
– –
(75,000) 2.27
– –
2020 12 31 – –
– –
– –
– –
2021 12 31 – –
2021 12 31 – –
2021 2020 12 31
2021 12 31
355 2021
19.
2016 2018
2019 12 31 26,852,267 10.72
18,820,581 14.20
(7,302,828) 10.88
(3,493,048) 11.36
2020 12 31 34,876,972 12.50
17,173,767 25.58
(10,703,381) 12.23
(5,264,376) 15.82
2021 12 31 36,082,982 18.33
2021 12 31 31,392,194 18.33
2021 12 31 469,862,000
2.6
2021 2020 12 31
12 31
2021 2020
114,357 92,999
126,355 90,482
240,712 183,481
2021 356
20.
2019 12 31 (9,291) 1,290 – (8,001)
23,475 1,073 (8,113) 16,435
(1)
– (1,492) – (1,492)
23,475 (419) (8,113) 14,943
2020 12 31 14,184 871 (8,113) 6,942
13,714 (4,504) 309 9,519
(1)
– (67) 1,556 1,489
13,714 (4,571) 1,865 11,008
2021 12 31 27,898 (3,700) (6,248) 17,950
(1)
357 2021
21.
2021 2020 12 31
2020 1 (ADS)
174.85 15,895,001 20.5%
2,779,241,000 2020 3 17
(BeiGene, Ltd.) 2020
9 24
20.6%
20.4%
(i) (ii)
2020 12 1
(a)
20% (b) 60 (c)2023 12
1
2020 7 S-3 333-238181
(Hillhouse Capital) Baker Bros. Advisors LP
145,838,979 0.0001 14.2308
185.00 2,069,610,000
421,443,000 29,614,832
2021 358
21.
2019 10 31 2019 12 6 2020 9 24
2021 9 165,529
2,151,877 50,000,000
2021 12
192.60
391.68 115,055,260
3,392,616,000
22.
10%
50%
359 2021
22.
2021 2020 12 31
10%
2021 2020 12 31
799,574,000 119,776,000
23.
2021 2020 12 31
63,772,000 23,717,000
401(k) 401(k) 401(k)
401(k)
2021 4% 2021 2020 12 31
401(k) 7,483,000 4,840,000
2021 2020 12 31 2,986,000
2,960,000
2021 360
23.
2021 2020 12 31
34,517,000 23,566,000 26,703,000 15,453,000
2020 12 31
20
2021 2020 12 31 AXA Pension Solutions AG
2022 1,604,000
2021 12 31
2022 44
2023 68
2024 528
2025 271
2026 197
2027 2031 3,760
4,868
361 2021
24.
2021 12 31 168,687,000 75,976,000
92,711,000
2021 12 31 42,394,000
1,250,000,000 2021 12
31 791,059,000
2021
12 31 27,985,000
15,000,000 2021 12 31
12,750,000
2021 362
24.
(CRO)
25.
383(1)(a) (b) (c) (f) 2
2021 2020 12 31
12 31
2021 2020
724 560
828 786
919 637
* 18,703 16,890
14 10
20,464 18,323
21,188 18,883
* 25 26
363 2021
25.
2021 2020 12 31
19
(a)
2021 2020 12 31
2021 12 31
Thomas Malley 89 – – 345 – 434
76 – – 345 – 421
Donald W. Glazer 70 – – 345 – 415
Michael Goller 73 – – 345 – 418
Ranjeev Krishana 76 – – 345 – 421
84 – – 345 – 429
72 – – 396 – 468
Corazon (Corsee) D. Sanders 92 – – 339 – 431
632 – – 2,805 – 3,437
2021 364
25.
(a)
2020 12 31
70 – – 290 – 360
Donald W. Glazer 63 – – 290 – 353
Michael Goller 61 – – 290 – 351
Ranjeev Krishana 63 – – 290 – 353
Thomas Malley 78 – – 290 – 368
73 – – 290 – 363
59 – – 445 – 504
Corazon (Corsee) D. Sanders 24 – – 118 – 142
491 – – 2,303 – 2,794
365 2021
25.
(b)
2021 2020 12 31
2021 2020 12 31
12 31
2021 2020
– –
828 786
919 637
15,553 14,376
14 10
17,314 15,809
17,314 15,809
2021 366
25.
(b)
2021 2020 12 31 Anthony C.
Hooper 2021 2020 12 31
27
2021 12 31
100 – 150 4,704 – 4,954
Anthony C. Hooper 92 – – 345 – 437
192 – 150 5,049 – 5,391
2020 12 31
100 – 150 6,157 – 6,407
Anthony C. Hooper 69 – – 211 – 280
169 – 150 6,368 – 6,687
367 2021
26.
2021 2020 12 31
25
2021 2020
2 2
3 3
5 5
12 31
2021 2020
1,983 1,732
1,385 1,037
17,646 13,268
32 33
21,046 16,070
2021 2020
25,000,001 30,000,000 – 1
30,000,001 35,000,000 – 1
35,000,001 40,000,000 2 –
60,000,001 65,000,000 – 1
80,000,001 85,000,000 1 –
3 3
2021 368
26.
2021 2020 12 31
19
27.
2021 2020 12 31
2021 12 31
(i) 100,000 2020 100,000 (ii)
150,000 2020 150,000 (iii) 241,839 2020 560,599
3,000,000 2020 4,000,000
(iv)39,000 1,000,000 2020
14A
369 2021
28.
12 31
2021 2020
517,173 290,646
495,265 18,228
163,845 –
1,176,283 308,874
2021 12 31 2021 12 31
379,607,000
115,658,000
2020 12 31
2021 12 31
2021 370
29.
2021 12 31
(i) (iii)
(1,459,239) (21,541) – (1,480,780)
(990,123) (27,189) – (1,017,312)
(1,438,588) (48,730) – (1,487,318)
25,234 5,253 (56,237) (25,750)
(1,413,354) (43,477) (56,237) (1,513,068)
(1,413,354) (43,477) (56,237) (1,513,068)
371 2021
29.
2020 12 31
(i) (iii)
(1,294,877) (5,338) – (1,300,215)
(600,176) (12,280) – (612,456)
(1,618,194) (17,618) – (1,635,812)
17,671 1,143 (41,404) (22,590)
(1,600,523) (16,475) (41,404) (1,658,402)
(1,596,906) (16,475) (41,404) (1,654,785)
2021 372
29.
2021 12 31
(i) (ii) (iii)
110,424 5,253 – – 125,744
10,067* – –
8,645,949 15,320 – – 8,661,269
11,191,007 48,730 – 56,237 11,809,005
125,319* 307,894* 79,818*
(4,966,103) (48,730) – (56,237) (5,568,781)
5,253 – –
(115,252)* (307,894)* (79,818)*
6,242,987 15,320 – – 6,258,307
373 2021
29.
2020 12 31
(i) (ii) (iii)
65,962 1,143 – – 76,029
8,924* – –
5,600,757 10,067 – – 5,610,824
7,414,932 17,618 – 41,404 7,927,963
107,701* 307,894* 38,414*
(3,552,749) (17,618) – (41,404) (4,055,713)
1,143 – –
(98,777)* (307,894)* (38,414)*
3,869,243 10,067 – – 3,879,310
*
2021 374
29.
(i)
2021 12 31
48,730,000 2020 17,618,000 2021 12
31 5,253,000 2020 1,143,000
125,319,000
10,067,000 2020 12 31
115,252,000 2020 12 31 2021 1 1
(ii)
375 2021
29.
(ii)
2016 2 307,894,000
307,894,000
(iii)
2016-
09
2021
12 31 2020 12 31
2021 12 31 56,237,000
2020 41,404,000
2020 12 31 79,818,000 79,818,000
2021 1 1
2021 376
29.
(iv)
2019 1 1
16
2021 12 31
2021 12 31
(v)
2021 12 31
2021 12 31
377 2021
30.
12 31
2021 2020
3,715,170 332,372
14 –
2,044,198 2,885,650
920,819 512,107
6,680,201 3,730,129
169,328 138,305
6,563 6,087
7,031 –
552,032 931,899
734,954 1,076,291
7,415,155 4,806,420
292,988 127,478
123,341 61,974
120,801 127,808
247,076 244,298
784,206 561,558
2021 378
30.
12 31
2021 2020
269,561 375,040
118,401 579
387,962 375,619
1,172,168 937,177
0.0001 9,500,000,000
2021 12 31 2020 12 31
1,334,804,281 1,190,821,941 133 118
11,191,007 7,414,932
17,950 6,942
(4,966,103) (3,552,749)
6,242,987 3,869,243
7,415,155 4,806,420
379 2021
30.
2019 12 31 801,340,698 79 2,925,970 (8,001) (1,955,843) 962,205
145,838,979 14 2,069,596 – – 2,069,610
206,635,013 21 2,162,386 – – 2,162,407
38,020,892 3 93,098 – – 93,101
(1,013,641) 1 – – – 1
– – 183,481 – – 183,481
– – (19,599) – – (19,599)
– – – 14,943 – 14,943
– – – – (1,596,906) (1,596,906)
2020 12 31 1,190,821,941 118 7,414,932 6,942 (3,552,749) 3,869,243
115,055,260 12 3,392,604 – – 3,392,616
2,151,877 – 50,000 – – 50,000
28,778,893 3 92,759 – – 92,762
(2,003,690) – – – – –
– – 240,712 – – 240,712
– – – 11,008 – 11,008
– – – – (1,413,354) (1,413,354)
2021 12 31 1,334,804,281 133 11,191,007 17,950 (4,966,103) 6,242,987
2021 380
31.
2021 12 31 2020 12 31
32.
2022 3 30
381 2021
2011 2011 4 15 2015 4 17 2011
2016 2016 1 14 2016
2020 4 28
2018 2018 11 7 2018 12 7
2018 2018 6 6
2018 2021 6 16
2021 9 1
2018 2018 6 6 2018 8 7
2018 2018
ADS 13
1987 4 7
2019 10 31
2020 1 2
2021 6 16
2021 12 15
2021 382
2010 10 28
2017 1 25
2017 3 3
BeiGene Switzerland GmbH 2017 9 1
BLA
NMPA (CDE)
CMO
622
CRO
383 2021
EMA (European Medicines Agency)
EUSA EUSA Pharma
FDA (U.S. Food and Drug Administration)
(General Data Protection Regulation)
(EU)2016/679
1998 11 27
GEM
2021 384
NMPA (National Medical Products Administration)
Novartis Pharma AG
2018 7 30
2021 12 31
sBLA
571
385 2021
2019 10 31
sNDA
15
2021 386
BRAF B-raf
B
BTK
cHL
CLL
Fcγ Fcγ
HCC
MCL
MZL
NSCLC
PARP ADP DNA
DNA
387 2021
PD-1 1 T pro-B
PD-L1 PD-L2 PD-1
T
RAF RAF BRAF-BRAF
BRAF-CRAF CRAF-CRAF
SLL
T T T
B
TIM-3 T 3 Th1
UC
WM
2021 388